ÖZGEÇMİŞ Prof. Dr. Cihan YURDAYDIN · seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a hepatitis D patient during

1

ÖZGEÇMİŞ

1. KİŞİSEL BİLGİLER

UNVANI ADI SOYADI:Prof. Dr. Cihan YURDAYDIN

DOĞUM TARİHİ ve YERİ:02.01.1954 Montreal, Kanada

2. EĞİTİM

ÖĞRENİM DÖNEMİ DERECE (*) ÜNİVERSİTE ÖĞRENİM ALANI

1971-1977 Lisans Ankara Üniversitesi Tıp Fakültesi (AÜTF)

Tıp

1978-1982 Uzmanlık Ankara Üniversitesi Tıp Fakültesi İç hastalıkları Ana Bilim Dalı

İç hastalıkları

1986-1989 Yan Dal Uzmanlığı

Ankara Üniversitesi Tıp Fakültesi Gastroenteroloji Bilim Dalı

Gastroenteroloji

3. AKADEMİK ve MESLEKİ DENEYİM

GÖREV DÖNEMİ UNVAN ÜNİVERSİTE BÖLÜM

1978-82 İç hastalıkları Asistanı

Ankara Üniversitesi Tıp Fakültesi, İç Hastalıkları Ana Bilim Dalı

1986-1989 Gastroenteroloji Yandal Asistanı

Ankara Üniversitesi Tıp Fakültesi, Gastroenteroloji Bilim Dalı

1989-1995 Doçent Ankara Üniversitesi Tıp Fakültesi, Gastroenteroloji Bilim Dalı

1995- Profesör Ankara Üniversitesi Tıp Fakültesi, Gastroenteroloji Bilim Dalı

4. BAŞLICA GÖREVLER ve TARİHLERİ

TARİH KURUM/KURULUŞ GÖREV

1978-1982 Ankara Üniversitesi Tıp Fakültesi (AÜTF), İç

hastalıkları ABD İç Hastalıkları uzmanı

1982-1983 Gümüşsuyu Askeri Hastanesi Dahiliye uzmanı

1984-1986 Van Devlet Hastanesi - zorunlu hizmet Dahiliye uzmanı

1986-1989 AÜTF Gastroenteroloji BD Gastroenteroloji üst ihtisası

Ocak-Aralık 1988 Viyana Üniversitesi Tıp Fak. Gastroenteroloji BD Research Fellow

1989-1995 AÜTF Gastroenteroloji BD Gastroenteroloji BD Doçenti

1991-1993 National Institute of Health, Liver Diseases Section Visiting Associate

1995-bugün AÜTF Gastroenteroloji BD. AÜTF Gastroenteroloji BD. Profesörü

2

2000-2017 AÜ Hepatoloji Enstütüsü AÜ Hepatoloji Enstütüsü Müdürü

2000-2003 European Association for the Study of the Liver Scientific Commitee üyesi

2013-2015 European Association for the Study of the Liver Educational Councillar

2001-2004 Association of National European and Mediterranean Societies of Gastroenterology (ASNEMGE)

Governing Board Üyesi

2009-2015 Dünya Gastroenteroloji Derneği (WGO) Genel Sekreter

2015-2017 Dunya Gastroenteroloji Dernegi (WGO) Baskan Yrd.

2017-halen Dünya Gastroenteroloji Derneği (WGO) Başkan

5. ANABİLİM DALI: İç Hastalıkları

ARAŞTIRMA ALAN(LAR)I: Viral Hepatit, Karaciğer hastalıklarının ekstrahepatik manifestasyonları (halsizlik, kaşıntı, hepatik ensefelopati)

ANAHTAR KELİMELER Türkçe: Hepatit B, Hepatit D, Hepatit C, Hepatik ensefelopati, Karaciğer Hastalığına

Bağlı Halsizlik İngilizce: Hepatitis B, Hepatitis D, Hepatitis C, Hepatic Encepholopathy, Fatigue of

Liver Disease

6. FAALİYET ve SORUMLULUKLAR (Hakemlik//Editörlük/Danışmanlık vb)

Hakemlik yaptığım dergiler 1- Gastroenterology

2- Hepatology

3- Journal of Hepatology 4- Lancet 5-Gut 6-Alimentary Pharmacology and Therapeutics 7- Journal of Viral Hepatitis 8- Journal of Clinical Virology 9- Antiviral Therapy 10- Liver International ve başkaları

Editör/Yardımcı Editör olduğum dergiler

1-Turkish Journal of Gastroenterology (editor) (2000-2013) 2- Liver International (yardımcı editor, 2010-2013) 3-European Journal of Gastroenterology and Hepatology (yayın kurulu) 4- Hepatology International (yayın kurulu) 5- World Journal of Gastroenterology (yayın kurulu)

7. BİLİMSEL KURULUŞ ÜYELİKLERİ (Yurtiçi ve yurtdışında üyesi olduğum bilimsel kuruluşlar)

1995-bugün: The American Association for the Study of Liver Diseases (AASLD) üyesi

3

1995-bugün: The European Association for the Study of the Liver (EASL) üyesi

1990-bugün: The Turkish Society for Gastroenterology üyesi

1993-bugün: The Turkish Association for the Study of the Liver and The Turkish Transplantation

Society üyesi

2004-bugün: ASNEMGE (Avrupa ve Akdeniz Ülkeleri Gastroenteroloji Derneği)Yönetici üyesi ve

Bilimsel Komite Başkanı

2001-2004 : The European Association for the Study of the Liver (EASL) Bilimsel komite üyesi

2013-2015: The European Association for the Study of the Liver (EASL) Educational Councillar

2009 Kasım- 2015:"World Gastroenterology Organization" (Dünya Gastroenterology Derneği) Genel

Sekreteri

2015-2017: WGO Baskan yardımcılığı

2017 Ekim- halen: WGO Başkanlığı

8. KAZANILAN ÖDÜLLER

2012 Bayındır Tıp Bilim Ödülü

2013 Tübitak Bilim Ödülü

2018 İstanbul Tabip Odası 14 Mart Tıp Bilim Ödülü

9. YAYINLAR

4

ULUSLARARASI DERGİLERDE YAYINLANMIŞ ARAŞTIRMA MAKALELERİ

NO / INDEX YAZAR(LAR); MAKALE BAŞLIĞI; DERGİ ADI; CİLT/SAYI/SAYFA; TARİH, MAKALE ADRESİ

* SCI kapsamlı dergilerdeki yayınları ifade eder

1*

SCI, SCIE

Zimmermann C, Ferenci P, Pifl C, Yurdaydın C, Ebner J, Lassmann H, Roth E,

HörtnaglH. Hepatic encephalopathy in thioacetamide induced acute liver failure in

rats.Characterization of an improved model and study of aminoacidergic

neurotransmission.Hepatology 1989; 9: 594-601.

2* SCI, SCIE

Yurdaydın C, Hörtnagl H, Steindl P, Zimmermann Ch, Pifl Ch, Singer E, Roth E, Ferenci

P: Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats

with thioacetamide-induced acute liver failure. Hepatology 1990; 12: 695-700.

3*

SCI, SCIE

Yurdaydın C, Gu ZQ, Nowak G, Fromm C, Holt AG, Basile AS. Benzodiazepine

receptor ligands are elevated in an animal model of hepatic encephalopathy:

relationshipbetween brain concentration and severity of encephalopathy. J Pharmacol Exp

Ther 1993;265: 565-71.

4*

SCI, SCIE

Örmeci N, Abasıyanık A, Bülbül M, Aka H, Atayurt H, Yurdaydın C, Dökmeci A,

Uzunalimoğlu Ö. Endoscopic papillotomy in a child with a biliocutaneous fistula.

Endoscopy 1994; 26: 565

5*

SCI, SCIE

Yurdaydın C, Li Y, Rothman R, Jones EA, Basile AS. Brain and plasma levels of opioid

peptides are altered in rats with thioacetamide-induced fulminant hepatic failure:

implications for the treatment of hepatic encephaloptahy with opiate antagonists. J

Pharmacol Exp Ther 1995; 273: 185-92

6* SCI, SCIE

Yurdaydın C, Walsh TJ, Engler HD, Ha J-H, Li Y, Jones EA, Basile AS. Gut bacteria

provide precursors of benzodiazepine receptor ligands in a rat model of hepatic

encephalopathy. Brain Res 1995; 679: 42-8.

7* SCI, SCIE

Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydın C,Turner ML, Schmitt JM,

Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritis of

cholestasis: a double-blind controlled trial. Ann Intern Med 1995; 123: 161-7.

8* SCI, SCIE

Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydın C, Swain M,

Kleiner DE, Mahaney K, Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A

randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.

9 SCIE Yurdaydın C, Herneth AM, Püspök A, Steindl P, Singer EA, Ferenci P. Modulation of

hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by

serotoninantagonists. Eur J Gastroenterol Hepatol 1996; 8: 667-71

10* SCI, SCIE

Beyler AR, Yurdaydın C, Bahar K, Gören A, Soykan I, Uzunalimoğlu Ö. Dilatation

therapy of upper esophageal webs in two cases of Plummer-Vinson syndrome:

Endoscopy1996; 28: 266-7.

11 SCIE Yurdaydın C, Swain MG, Mininberg ED, Vergella J, Kleiner D, Paul SM, Jones EA.

Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular

necrosis. Eur J Gastroenterol Hepatol 1998; 10: 503-7.

12* SCI, SCIE

Yurdaydın C, Karavelioğlu D, Onaran O, Çelik T, Yaşa MH, Uzunalimoğlu Ö. Opioid

receptor ligands in human hepatic encephalopathy. J Hepatol 1998; 29: 796-801.

13*

SCI, SCIE

Çelik T, Uzbay T, Çınar K, Bozkaya H, Uzunalimoğlu Ö, Yurdaydın C. Combination

treatment of thioacetamide-induced fulminant hepatic failure in the rat with

benzodiazepine and opioid receptor antagonists. J Hepatol 1999; 31: 880-6.

14*

SCI, SCIE

Akbay A, Çınar K, Uzunalimoğlu Ö, Eranıl S, Yurdaydın C, Bozkaya H, Bozdayı AM.

Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide

hepatotoxicity of rats. Hum Exp Toxicol. 1999; 18: 669-76

15* SCI, SCIE

Bozdayı AM, Uzunalimoğlu O, Aslan N, Bozkaya H, Türkyılmaz AR, Kayhan B, Şahin

B, Sivri B, Uygun A, Altıok A, Çetinkaya H, Karayalçın S, Yurdaydın C. Influence of

viral load and alanine aminotransferase on viral genetic heterogenity in patiens with

5

chronic hepatitis C virus infection. Intervirology 2000; 43: 61-6.

16*

SCI, SCIE

Bozkaya H, Bozdayı AM, Türkyılmaz A, Çetinkaya H, Yurdaydın C, Uzunalimoğlu Ö.

TH1/TH2 Cytokines and their relations to HBeAg status and ALT flares in chronic HBV

infection. Hepatogastroenterology 2000; 47: 1667-71

17*

SCI, SCIE

Bozkaya H, Bozdayı AM, Aslan N, Çetinkaya H, Akdoğan M, Şentürk H, Akkız H,

Yurdaydın C, Karayalçın S, Uzunalimoğlu Ö. Circulating IL-2 and IL-10 in chronic

activehepatitis C with respect to the response to IFN treatment. Infection 2000; 28: 309-

13.

18* SCI, SCIE

Uzunalimoğlu Ö, Yurdaydın C, Çetinkaya H, Bozkaya H, Şahin T, Çolakoğlu S, Tankut

E, Sarıoğlu M, Özenirler S, Akkız H, Tözün N. Risk factors for hepatocellular carcinoma

in Turkey. Dig Dis Sci 2001 May; 46(5) :1022-8

19*

SCI, SCIE

Bozkaya H, Bozdayı M , Türkyılmaz R, Sarıoğlu M, Çetinkaya H, Çınar K, Köse K,

Yurdaydin C, Uzunalimoğlu O. Circulating IL-2, IL-10 and TNF-alpha in chronic

hepatitis B: their relations to HB status and the activity of liver disease.

Hepatogastroenterology. 2000 Nov-Dec; 47 (36): 1675-9

20*

SCI, SCIE

Bozdayı AM, Bozkaya H, Türkyılmaz AR, Saryodlu M, Çetinkaya H, Karayalçın S,

Yurdaydin C, Uzunalimoğlu. Nucleotide divergences in the core promoter and precore

region of genotype D hepati virus in patients with persistently elevat normal ALT levels.

JClin Virol. 2001 Apr ; 21(1): 91-101.

21* SCI, SCIE

Yurdaydin C, Bozkaya H, Gürel S, Tillmann HL, Aslan N, Okcu-Heper A, Erden E,

Yalçın K, Iliman N, Uzunalimoglu O, Manns MP, Bozdayı AM. Famciclovir treatment

ofchronic delta hepatitis. J Hepatol. 2002 Aug;37(2):266-71

22*

SCI, SCIE

Bozkaya H, Yurdaydin C, Törüner M, Arat M, Bozdayı AM, Erekul S, Çinar K, Koç H,

Uzunalimoğlu O. Remission of severe aplastic anemia asso with hepatitis B virus

infection after viral clearance: potential role of lamivudine. Dig Dis Sci. 2002; 47:1782-5

23*

SCI, SCIE

Bozkaya H, Yurdaydin C, Bozdayı AM, Erkan O, Karayalçın S, Uzunalimoğlu O.. Oral

ganciclovir for treatment of lamivudin resistant hepatitis B virus infection: a pilot study.

Clin Infect Dis. 2002 ; 35: 960-5

24* SCI, SCIE

Erden A, Erden I, Karayalçın S, Yurdayin C. Budd-Chiari syndrome: evaluation with

multiphase contrast-enhanced three-dimensional MR angiography. AJR Am J

Roentgenol.2002; 179: 1287-9.

25* SCI, SCIE

Serinöz E, Varlı M, Erden E, Çinar K, Kansu A, Uzunalimoğlu O, Yurdaydin C, Bozkaya

H. Nuclear localization of hepatitis B core ant and its relations to liver injury, hepatocyte

proliferation, and viral load. J Clin Gastroenterol 2003; 36:269-72.

26

SCIE Erden A, Erden I, Yagmurlu B, Karayalçın S, Yurdaydin C, Karayalçin K. Portal venous

system Evaluation with cont enhanced 3D MR portography. Clin Imaging. 2003; 27:101-

5.

27

SCIE Yalçın K, Degertekin H, Yurdaydin C, Bozdayı M, Bozkaya H. The role of HbeAg

seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D

virus infection in a hepatitis D patient during alpha-interferon therapy. Eur J Gastroenterol

Hepatol. 2003; 15: 81.

28*

SCI, SCIE

Bozdayı AM, Uzunalimoğlu O, Türkyılmaz AR, Aslan N, Sezgin O, Şahin T, Bozdayı G,

Çinar K, Pai SB, Pai R, Bozkaya H, Karayalçın S, Yurdaydin C, Schinazi RF. YSDD: a

novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral

Hepat. 2003;10:256-26

29 SCIE Erden A, Erden I, Yurdaydin C, Karayalcin S. Hepatic outflow obstruction: enhancement

patterns of the liver on MR angiography. Eur J Radiol 2003; 48:203-8

30* SCI, SCIE

Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Ozden A. Barrett's esophagus:

prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol. 2004;

6

19:535-540

31*

SCI, SCIE

Bozkaya H, Bektas M, Metin O, Erkan O, Ibrahimoglu D, Dalva K, Akbiyik F, Gurel S,

Bozdayi AM, Akay C, Yurdaydin C, Aslan O, Uzunalimoglu O. Screening for

hemochromatosis in Turkey. Dig Dis Sci. 2004; 49:444-449

32*

SCI, SCIE

Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C,

Uzunalimoglu O, Bozkaya H. Ligand-induced expression of peroxisome

proliferatoractivated receptor alpha and activation of fatty acid oxidation enzymes in fatty

liver. Eur J Clin Invest. 2004; 34:429-435

33*

SCI, SCIE

Bozdayi AM, Eyigun CP, Turkyilmaz AR, Avci IY, Pahsa A, Yurdaydin C. A novel

pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S)

mutation selected during lamivudine therapy and successful treatment with adefovir

dipivoxil. J Clin Virol 2004; 31:76-77

34 SCIE Karavelioglu D, Koytak ES, Bozkaya H, Uzunalimoglu O, Bozdayi AM, Yurdaydin C.

Lichen planus and HCV infection in Turkish patients. Turk J Gastroenterol. 2004; 15:133-

136

35*

SCI, SCIE

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T,

Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N;

Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients

withHBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351:1206-1217

36*

SCI, SCIE

Bozdayi AM, Aslan N, Bozdayi G, Turkyilmaz AR, Sengezer T, Wend U, Erkan O,

Aydemir F, Zakirhodjaev S, Orucov S, Bozkaya H, Gerlich W, Karayalcin S, Yurdaydin

C, Uzunalimoglu O. Molecular epidemiology of hepatitis B, C and D viruses in Turkish

patients. Arch Virol. 2004; 149:2115-2129

37 SCIE Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, Karayalcin S, Ozden A,

Bozkaya H, Yurdaydin C, Uzunalimoglu O. Thrombophilic gene mutations in cirrhotic

patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17:339-43

38* SCI, SCIE

Yurdaydin C, Bozkaya H, et al. Treatment of HBeAg-negative chronic hepatitis B with

lamivudine vs. lamivudine + interferon. J Viral Hepat 2005; 12:262-268

39*

SCI, SCIE

Celik T, Goren MZ, Cinar K, Gurdal H, Onder FO, Tan A, Terzioglu B, Bozdayi AM,

Bozkaya H, Uzunalimoglu O, Yurdaydin C. Fatigue of cholestasis and the serotoninergic

neurotransmitter system in the rat. Hepatology 2005; 41:731-737

40*

SCI, SCIE

Bozkaya H, Yurdaydin C, Idilman R, Tuzun A, Cinar K, Erkan O, Bozdayi AM, Erden E,

Uzun Y, Cetinkaya H, Uzunalimoglu O. Lamivudine treatment in HBeAg-negative

chronic hepatitis B patients with low level viraemia. Antivir Ther 2005;10:319-25

41*

SCI, SCIE

Bozdayi G, Turkyilmaz AR, Idilman R, Karatayli E, Rota S, Yurdaydin C, Bozdayi AM.

Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from

turkish patients with chronic HBV infection. J Med Virol 2005; 76:476-81.

42*

SCI, SCIE

Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin

C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus

during lamivudine therapy. Antimicrob Agents Chemother 2005; 49:2618-24

43

SCIE Toruner M, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, Uzunalimoglu O,

Ozden A. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in

inflammatory bowel disease. Turk J Gastroenterol 2004; 15:250-2

44

SCIE Varlı M, Heper AO, Erden E, Uzunalimoglu, Yurdaydın C, Bozkaya. P21 expression and

its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus

infection. Turk J Gastroenterol. 2005; 16:12-6.

7

45*

SCI, SCIE

Verdi H, Koytak ES, Onder O, Ergul AA, Cinar K, Idilman R, Erden E, Bozdayi AM,

Yurdaydin C, Uzunalimoglu O, Bozkaya H. Peroxisome proliferator-activated receptor

alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C

virus-related liver steatosis. J Investig Med 2005; 53:353-9

46*

SCI, SCIE

Terzioglu B, Aypak C, Yananli HR, Kucukibrahimoglu E, Yurdaydin C, Goren MZ. 5-

hydroxytryptamine release in the anterior hypothalamic and the hippocampal areas of

cholestatic rats. Life Sci. 2006; 78:1078-83

47*

SCI, SCIE

Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska

A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026

BEHoLD Study Group.Entecavir for treatment of lamivudine-refractory, HBeAg-positive

chronic hepatitis B. Gastroenterology 2006; 130:2039-4

48*

SCI, SCIE

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G,

Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto M, Farci P, Popescu M, McCloud P.

Predicting response to peginterferon alfa-2a, lamivudine and the two combined for

HBeAg-negative chronic hepatitis B. Gut. 2007

49*

SCI, SCIE

Karataylı E, Karayalçın S, Karraaslan H, Türyılmaz AR, Şahin F, Yurdaydın C, Bozdayı

AM. A novel mutation pattern emerging during lamivudine treatment shows cross-

resistance to adefovir dipivoxil. Antiviral Ther 2007; 12:761-8

50* SCI, SCIE

Ferenci P, Czlonkowska A, Merle U, Gromadzka G, Yurdaydın C, et al. Late onset

Wison’s disease. Gastroenterology 2007; 132:1294-9

51* SCI, SCIE

Yurdaydın C, Bozkaya H, Karaaslan H, et al. A pilot study of 2 years of interferon

treatment in patients with chronic delta hepatitis. J Viral Hepat 2007; 14:812-6

52* SCI, SCIE

Koytak ES, Yurdaydin C, Glenn J. Hepatitis D. Curr Treat Options Gastroenterol 2007;

10:456-63

53* SCI, SCIE

Yurdaydın C, Bozkaya H, Önder FO, et al. Treatment of chronic delta hepatitis with

lamivudine vs. lamivudine + interferon vs. interferon. J Viral Hepat 2008; 15:314-21

54*

SCI, SCIE

Değertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in

patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int

2008; 28:494-8

55* SCI, SCIE

Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir

therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical,

and serology outcomes through 96 weeks. Hepatology; 2008; 48:99-10

56*

SCI, SCIE

Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu

ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic

Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3

years after treatment with peginterferon alfa-2a. Gastroenterology 2009 136:2169-2179

57*

SCI, SCIE

Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B,

Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin

C. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic

hepatitis B patients. J Viral Hepat. 2009; 16:279-85

58

SCIE Koytak ES, Mizrak D, Bektaş M, Verdi H, Arslan Ergül A, Idilman R, Cinar K,

Yurdaydin C, Ersõz S, Karayalçin K, Uzunalimoğlu O, Bozkaya H. PPAR-alpha L162V

polymorphism in human hepatocellular carcinoma. Turk J Gastroenterol. 2008; 19:245-9

59 SCIE Yurdaydin C. Entecavir: a step forward in combating hepatitis B disease. Expert Opin

Pharmacother. 2008; 9:3095-109

60 SCIE Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, Dagli U, Ulker A,

Hulagu S, Akpinar H, Tuncer C, Suleymanlar I, Ovunc O, Hilmioglu F, Aslan S,

Turkdogan K, Bahcecioglu HI, Yurdaydin C; Members of the Turkish IBD Study Group.

8

Clinical Characteristics of Inflammatory Bowel Disease in Turkey: A Multicenter

Epidemiologic Survey. J Clin Gastroenterol. 2009; 43:51-7

61*

SCI, SCIE

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo

K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus

surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg

negative chronic hepatitis B.Hepatology 2009; 49:1141-50

62*

SCI, SCIE

Bektaş M, Dökmeci A, Cinar K, Halici I, Oztas E, Karayalcin S, Idilman R, Sarioglu M,

Ustun Y, Nazligul Y, Ormeci N, Ozkan H, Bozkaya H, Yurdaydin C. Endoscopic

Management of Biliary Parasitic Diseases. Dig Dis Sci 2010; 55:1472-8

63

SCIE Mizrak D, Engin B, Onder FO, Yener B, Bektaş M, Biyikli Z, Idilman R, Cinar K,

Karayalçin K, Ersöz S, Karayalçin S, Ozden A, Yurdaydin C, Yazihan N, Ataoğlu H,

Bozkaya H, Uzunalimoğlu O. Aflatoxin exposure in viral hepatitis patients in Turkey.

Turk J Gastroenterol. 2009 Sep; 20:192-7

64* SCI, SCIE

Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in

chronic delta hepatitis. Liver Int 2010; 30:430-7

65*

SCI, SCIE

Idilman R, Bektas M, Cinar K, Toruner M, Cerit ET, Doganay B, Erden E, Bozkaya H,

Bahar K, Karayalcin S, Soykan I, Palabiyikoglu M, Cetinkaya H, Yurdaydin C, Dokmeci

A, Ozden A. The characteristics and clinical outcome of drug-induced liver injury: a

single-center experience. J Clin Gastroenterol. 2010 Jul;44(6):e128-32

66* SCI, SCIE

Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either

drug alone for hepatitis delta. N Engl J Med 2011; 364:322-31

67*

SCI, SCIE

Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion

JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging

M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T,

Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman

E, Negro F, Zeuzem S. A systemic review of hepatitis C virus epidemiology ın Europe,

Canada and Israel. Liver Int 2011; 31(Suppl. 2) :30-60

68* SCI, SCIE

Grabowski J, Yurdaydìn C, Zachou K, et al. Hepatitis D virus-specific cytokine responses

in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver

Int 2011; 31(9):1395-405

69* SCI, SCIE

Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the

peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver

transplantation. J Hepatol 2011; 56(1):115-2

70

SCIE Seven G, Karatayli SC, Köse SK, Yakut M, Kabaçam G, Törüner M, Heper AO, Voelker

M, Erden E, Bozdayi AM, Uzunalımoğlu O, Bozkaya H, Yurdaydin C, Schuppan D.

Serum connective tissue markers as predictors of advanced fibrosis in patients with

chronic hepatitis B and D. Turk J Gastroenterol 2011; 22(3):305-14

71*

SCI, SCIE

Celik I, Karatayli E, Cevik E, Kabakçi SG, Karatayli SC, Dinç B, Cinar K, Yalçin K,

Idilman R, Yurdaydin C, Bozdayi AM. Complete genome sequences and phylogenetic

analysis of hepatitis delta viruses isolated from nine Turkish patients. Arch Virol 2011;

156(12):2215-20

72*

SCI, SCIE

Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C,

Bozdayi AM. Molecular characterization of a novel entecavir mutation pattern isolated

from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol 2011;

53(2):130-4

73* SCI, SCIE

Mederacke I, Yurdaydin C, Dalekos GN, et al. Anti-HDV immunoglobulin M testing

inhepatitis delta revisited: correlations with disease activity and response to

pegylatedinterferon-α2a treatment. Antivir Ther. 2012;17(2):305-12

74* SCI, SCIE

Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K.

Hepatitis B surface antigen seroconversion is associated with favourable long-term

clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B

9

patients. J Viral Hepat. 2012; 19(3):220-6

75 SCIE Quigley EM, Yurdaydin C. First WGO regional meeting with the TSG: a template for

future regional gastroenterology collaborations. Expert Rev Gastroenterol Hepatol. 2012

Apr;6(2):141-3

76* SCI, SCIE

Yurdaydin C, Quigley EM. Gastro-Antalya 2011: A Successful Regional Meeting

Between the WGO and the TSG. J Clin Gastroenterol. 2012 Apr;46(4):i-ii

77

SCIE Bozdayi AM, Karatayli SC, Alagöz SG, Mizrak D, Sayki M, Ozkan M, Savaş B, Erden E,

Cinar K, Idılman R, Yurdaydin C. Potential proteomic biomarkers in assessing liver

fibrosis using SELDI-TOF MS. Turk J Gastroeneterol 2012; 23:46-53

78* SCI, SCIE

Kabaçam G, Önder FO,Yakut M, Seven G, Karataylı SC. Karataylı E, Savaş B, Idilman

R, Bozdayı AM, Yurdaydın C. Entecavir treatment of chronic delta hepatitis. Clin Inf Dis

2012

79*

SCI, SCIE

I. Mederacke, S. Gurel, C. Yurdaydin, S. Zeuzem, A. Großhennig, K. Zachou, A.

Erhardt, C. Chatzikyrkou, Y. Cakaloglu, H. Bozkaya, K. Yalcin, G. N. Dalekos, M. P.

Manns and H. Wedemeyer on behalf of Hep-Net/International Delta Hepatitis Study

Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either

drug alone in hepatitis B/D co-infection. Journal of Viral Hepatitis, 2012, 19, 387–395

80*

SCI, SCIE

Heidrich B, C Serrano B, Idilman R, Kabaçam G, Bremer B, Raupach R, Onder

FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL,Bozdayi

AM, Manns MP, Yurdaydın C, Wedemeyer H HBeAg positive hepatitis delta: virological

patterns and clinical longterm outcome HBeAg-positivehepatitis delta.. Liver Int. 2012

Jun 20. doi: 10.1111/j.1478-3231.2012.02831.x. [Epub ahead of print]

81* SCI, SCIE

Kayhan H, Karatayli E, Turkyilmaz AR, Sahin F, Yurdaydin C, Bozdayi AM.

Inhibition of hepatitis B virus replication by shRNAs in stably HBV expressed HEPG2

2.2.15 celllines. Arch Virol. 2007;152(5):871-9. Epub 2007 Jan 25

82* SCI, SCIE

Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann

B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H.

Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat. 2006 Aug;13(8):505-14

83* SCI, SCIE

Uzun Y, Bozkaya H, Erden E, Cinar K, Idilman R, Yurdaydin C, Uzunalimoglu O.

Hepatitis B core antigen expression pattern reflects the response to anti -viral treatment. J

Gastroenterol Hepatol. 2006 Jun;21(6):977-81

84

SCIE Tasci I, Mas MR, Vural SA, Deveci S, Comert B, Alcigir G, Mas N, Akay C, Bozdayi

M, Yurdaydin C, Bozkaya H, Uzunalimoglu O, Isik AT, Said HM. Pegylated interferon

alpha plus taurine in treatment of rat liver fibrosis. World J Gastroenterol. 2007

Jun21;13(23):3237-44

85*

SSCI Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M,

Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The costeffectiveness of treating chronic

hepatitis B patients ina median endemic and middle income country. Eur J Health Econ.

2012 Jul 20. [Epub ahead of print]

86* SCI, SCIE

Yurdaydin C, Mullen KD, Bergasa NV. Obituary: E. Anthony Jones, M.D. Liver Int 2012;

32:871-2

87* SCI, SCIE

Yurdaydın C. Treatment of chronic delta hepatitis. Sem Liver Dis 2012. Semin Liver Dis.

2012 Aug;32(3):237-44.

88*

SCI, SCIE

Karatayli E, Idilman R, Karatayli SC, Cevik E, Yakut M, Seven G, Kabaçam G, Bozdayi

AM, Yurdaydin C. Clonal Analysis of the Quasispecies of Antiviral Resistant HBV

Genomes in Patients with Entecavir Resistance Treated with Rescue Lamivudine Adefovir

Combination Therapy. Antivir Ther. 2013;18(1):77-85

89*

SCI, SCIE

Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG,

Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C,

Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and

lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.J Viral

http://www.ncbi.nlm.nih.gov/pubmed/22967105


10

Hepat. 2012 Oct;19(10):732-43.

90*

SCI, SCIE

Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin

C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, Nomura T, Chen Y, Zheng M,

Fitch WL, Peltz G. Using chimeric mice with humanized livers to predict human drug

metabolism and a drug-drug interaction.J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.

doi: 10.1124/jpet.112.198697. Epub 2012 Nov 8. Erratum in: J Pharmacol Exp Ther. 2013

May;345(2):327.

91

SCIE Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak

F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin

C. Pegylated interferon-based treatment in patients with advanced liver disease due to

chronic delta hepatitis.Turk J Gastroenterol. 2012;23(5):560-8.

92*

SCI, SCIE

Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V,

Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year

response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.Hepatol Int.

2013 Mar;7(1):88-97. Epub 2012 Mar 23

93*

SCI, SCIE

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V,

Regep L, Bonino F. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB:

on-treatment kinetics of HBsAg serum levels vary by HBV genotype.J Hepatol. 2013

Dec;59(6):1153-9.

94*

SCI, SCIE

Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt

A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; the HIDIT-1

Study Group. Role of immunohistochemistry for hepatitis D and hepatitis B virus in

hepatitis delta. Liver Int. 2013 Nov 5. doi: 10.1111/liv.12376. [Epub ahead of print]

95*

SCI, SCIE

Keskin O, Ormeci AC, Baran B, Kabaçam G, Tuzun A, Karatayli E, Akyüz F, Karatayli

S, Bozdayi AM, Onel D, Badur S, Idilman R, Kaymakoglu S, Yurdaydin C. Efficacy of

tenofovir in adefovir-experienced patients compared to treatment-naive patients with

chronic hepatitis B.Antivir Ther. 2014 Feb 12. doi: 10.3851/IMP2732. [Epub ahead of

print]

96*

SCI, SCIE

Bektas M, Seven G, Idilman R, Yakut M, Doğanay B, Kabacam G, Ustun Y, Korkut E,

Kalkan C, Sahin G, Cetinkaya H, Bozkaya H, Yurdaydin C, Bahar K, Cinar K, Soykan I.

Manometric assessment of esophageal motor function in patients with primary biliary

cirrhosis.Eur J Intern Med. 2014 Feb 14. pii: S0953-6205(14)00009-0. doi:

10.1016/j.ejim.2014.01.008. [Epub ahead of print

97*

SCI, SCIE

Karatayli E, Altunoglu YC, Karatayli SC, Alagoz SGK, Cinar K, Yalcin K, İdilman R,

Yurdaydin C, Bozdayi AM. A one step real time PCR method for the quantification of

hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal

control. Journal of Clinical Virology, 2014 (in press:

http://dx.doi.org/10.1016/j.jcv.2014.01.021)

98*

SCI,

SCIE

Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN,

Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP,

Wedemeyer H; HIDIT-1 Study Group.Late HDV RNA relapse after peginterferon alpha-

based therapy of chronic hepatitis delta.

Hepatology. 2014 Jul;60(1):87-97. doi: 10.1002/hep.27102.

99*

SCI,

SCIE

Wiegand J, Wedemeyer H, Franke A, Rößler S, Zeuzem S, Teuber G, Wächtler M,

Römmele U, Ruf B, Spengler U, Trautwein C, Bock CT, Fiedler GM, Thiery J, Manns

MP, Brosteanu O, Tillmann HL; German Hep-Net Acute Hepatitis B (GAHB) Study

Group.Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a

prospective randomized double-blinded multicentre trial.J Viral Hepat. 2014

Oct;21(10):744-50. doi: 10.1111/jvh.12210. Epub 2013 Dec 11.
















http://www.sciencedirect.com/science/journal/13866532

http://dx.doi.org/10.1016/j.jcv.2014.01.021

https://www.ncbi.nlm.nih.gov/pubmed/24585488




11

100*

SCI,

SCIE

Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN,

Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP,

Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-

based therapy of chronic hepatitis delta.Hepatology. 2014 Jul;60(1):87-97. doi:

10.1002/hep.27102.

101*

SCI,

SCIE

Karatayli SC, Ulger ZE, Ergul AA, Keskin O, Karatayli E, Albayrak R, Ozkan M, Idilman

R, Yalcin K, Bozkaya H, Uzunalimoğlu O, Yurdaydin C, Bozdayi AM. Tumour necrosis

factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene

polymorphisms in patients with chronic hepatitis delta.J Viral Hepat. 2014 Apr;21(4):297-

304. doi: 10.1111/jvh.12139. Epub 2013 Jul 22.

102*

SCI,

SCIE

Karataylı SC, Bozdayı M, Karataylı E, Öztürk T, Husseini AA, Albayrak R, Özkan M,

Kalaylıoğlu Z, Yalçın K, Çınar K, İdilman R, Yurdaydın C. Interleukin-28 gene

polymorphisms may contribute to HBsAg persistence and the development of HBeAg-

negative chronic hepatitis B.Liver Int. 2015 Mar;35(3):846-53. doi: 10.1111/liv.12595.

Epub 2014 Jun 10.

103*

SCI,

SCIE

Karataylı E, Altunoğlu YÇ, Karataylı SC, Yurdaydın C, Bozdayı AM. Free circulating

nucleic acids in plasma and serum as a novel approach to the use of internal controls in

real time PCR based detection.J Virol Methods. 2014 Oct;207:133-7. doi:

10.1016/j.jviromet.2014.07.008. Epub 2014 Jul 14.

104*

SCI,

SCIE

Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K,

Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski

J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns

MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Anti-HDV IgM as a marker of

disease activity in hepatitis delta.PLoS One. 2014 Jul 29;9(7):e101002. doi:

10.1371/journal.pone.0101002. eCollection 2014.

105*

SCI,

SCIE

Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V,

Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE,

Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico

P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B

patients receiving entecavir or tenofovir.J Hepatol. 2015 Feb;62(2):363-70. doi:

10.1016/j.jhep.2014.08.045. Epub 2014 Sep 6.

106

SCI-E Kabakçı Alagöz G, Karataylı SC, Karataylı E, Celik E, Keskin O, Dinç B, Cınar K,

Idilman R, Yurdaydın C, Bozdayı AM. Hepatitis C virus genotype distribution in Turkey

remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1,

and 5'UTR regions in genotyping efficiency.Turk J Gastroenterol. 2014 Aug;25(4):405-

10. doi: 10.5152/tjg.2014.7083.

107*

SCI,

SCIE

Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca

US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in

treatment-naïve chronic hepatitis B patients in the real-world setting.J Viral Hepat. 2015

May;22(5):504-10. doi: 10.1111/jvh.12358. Epub 2014 Nov 28.

108*

SCI,

SCIE

Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B,

Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns

M, Yurdaydin C. Association Between Level of Hepatitis D Virus RNA at Week 24 of

Pegylated Interferon Therapy and Outcome.Clin Gastroenterol Hepatol. 2015

Dec;13(13):2342-49.e1-2. doi: 10.1016/j.cgh.2015.05.029.























12

109*

SCI,

SCIE

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA,

Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ,

Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation

inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised,

double-blind, placebo-controlled phase 2A trial.Lancet Infect Dis. 2015 Oct;15(10):1167-

1174. doi: 10.1016/S1473-3099(15)00074-2

110*

SCI,

SCIE

Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi

H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J,

Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen

HL, Lampertico P.PAGE-B predicts the risk of developing hepatocellular carcinoma in

Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol. 2016

Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035.

111*

SCI,

SCIE

Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J,

Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer

H, Heidrich B.Non-invasive fibrosis score for hepatitis delta.

Liver Int. 2017 Feb;37(2):196-204. doi: 10.1111/liv.13205.

112*

SCI,

SCIE

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA,

Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee

LJ, Elkhashab M, Berg T, Sporea I, Yurdaydin C, Husa P, Jablkowski MS, Gane

E.Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine

resistant hepatitis B: A 5-year randomised study.J Hepatol. 2017 Jan;66(1):11-18. doi:

10.1016/j.jhep.2016.08.008

113*

SCI,

SCIE

Karakaya F, Özer S, Kalkan Ç, Tüzün EA, Çalışkan A, Keskin O, Kabaçam G, Karatayli

S, Karatayli E, Bozdayi AM, Idilman R, Yurdaydin C.Discontinuation of lamivudine

treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-

up.Antivir Ther. 2017;22(7):559-570. doi: 10.3851/IMP3144

114*

SCI,

SCIE

Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL,

Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N,

Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I,

Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico

P.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or

tenofovir in Caucasians with chronic hepatitis B.Hepatology. 2017 Nov;66(5):1444-1453.

doi: 10.1002/hep.29320.

115*

SCI,

SCIE

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN,

Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P,

Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C,

Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Clinical and

virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis

Delta International Network (HDIN).

Liver Int. 2017 Sep 29. doi: 10.1111/liv.13604

116*

SCI,

Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S,

Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS. Optimizing lonafarnib treatment for

the management of chronic delta hepatitis: The lowr HDV - 1 study. Hepatology. 2017

Nov 20. doi: 10.1002/hep.29658.

















13

SCIE

117*

SCI,

SCIE

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman

R, Yurdaydin C, Glenn JS, Heller T, Dahari H.Pharmacokinetics and pharmacodynamics

modeling of lonafarnib in patients with chronic hepatitis delta virus infection.Hepatol

Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.104

118*

SCI,

SCIE

Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çaliskan A, Kabaçam G, Önder FO,

Karatayli S, Karatayli E, Deda X, Bozkaya H, Bozdayi AM, Idilman R. Interferon

Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural

Course of the Disease.J Infect Dis. 2018 Feb 7. doi: 10.1093/infdis/jix656

119*

SCI,

SCIE

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, Van Boemmel F, Buti M, Goulis

J, Luis Calleja J, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın

O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I,

Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P.8-

year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy

is similar to the general population.

J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30081-3. doi: 10.1016/j.jhep.2018.01.031

ULUSLARARASI DERLEME MAKALELERİ

NO /

INDEX

YAZAR(LAR); MAKALE BAŞLIĞI; DERGİ ADI; CİLT/SAYI/SAYFA; TARİH,

MAKALE ADRESİ

1* SCI,

SCIE

Craxi A, Yurdaydın C. From viral pathobiology to the treatment of hepatitis B virus

infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). J

Hepatol 2006; 44:1186-95

2* SCI,

SCIE

Yurdaydın C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of

chronic delta hepatitis.J Viral Hepat 2010; 17:749-56

3

SCIE Toy M, Onder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen

J, Richardus JH, Yurdaydin C. Age- and region-specific hepatitis B prevalence in Turkey

estimated using generalized linear mixed models: a systematic review. BMC Infect Dis

2011; 11(1):337

4* SCI,

SCIE

Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M,

Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and

ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011 8(4):212-23

5* SCI,

SCIE

Yurdaydın C. The central opioid system in liver disease and its complications. Met Brain

Dis 2001 Jun; 16 (1-2): 79-83.

6 SCIE Jones EA, Yurdaydın C, Basile AS. The GABA hypothesis-state of the art. Adv Exp Med

Biol 1994; 368:89-101.

7 SCIE Jones EA, Basile AS, Yurdaydın C, Skoluick P. Do benzodiazepine ligands contribute to

hepatic encephalopathy? Adv Exp Med Biol 1993; 341: 57-69.

8*

SCI,

SCIE,

SSCI

Jones EA, Yurdaydın C, Basile AS. The role of endogenous benzodiazepines in hepatic

encephalopathy: animal studies. Alcohol & Alcoholism Suppl, 1993; 2:175-80.

9

Yurdaydin C, Idilman R.Therapy of Delta Hepatitis.

Cold Spring Harb Perspect Med. 2015 Aug 7;5(10). pii: a021543. doi:

10.1101/cshperspect.a021543. Review.










14

10

Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim

K, Piratvisuth T, Shah S, Shiffman ML, Tacke F, Tan SS, Tanwandee T, Win

KM, Yurdaydin C.Management of hepatitis C virus infection in the Asia-Pacific region:

an update.Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. doi: 10.1016/S2468-

1253(16)30080-2. Epub 2016 Dec 10. Review

11

Yurdaydin C.Recent advances in managing hepatitis D.

F1000Res. 2017 Aug 30;6:1596. doi: 10.12688/f1000research.11796.1. eCollection 2017.

Review

12

SCI-E

Tabak F, Yurdaydın C, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, Alkım C, Çekin

AH, Çuvalcı NÖ, Demir K, Değertekin B, Dökmetaş İ, Ersöz G, Hizel K, Kandemir FÖ,

Önlen Y, Sonsuz A, Şenateş E, Tosun S, Tözün N, Idilman R, Guidelines Study Group

VH.Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017

Clinical Practice Guidelines.Turk J Gastroenterol. 2017 Dec;28(Suppl 2):73-83. doi:

10.5152/tjg.2017.19

13

SCI-E Yurdaydın C, Tabak F, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, Alkım C, Çekin

AH, Çuvalcı NÖ, Demir K, Değertekin B, Dökmetaş İ, Ersöz G, Hizel K, Kandemir FÖ,

Önlen Y, Sonsuz A, Şenateş E, Tosun S, Tözün N, Idilman R, Guidelines Study Group

VH. Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017

Clinical Practice Guidelines.Turk J Gastroenterol. 2017 Dec;28(Suppl 2):84-89. doi:

10.5152/tjg.2017.20

EDITORIAL, OLGU SUNUMU, EDİTÖRE MEKTUP GİBİ DİĞER YAYINLAR

NO /

INDEX

YAZAR(LAR); MAKALE BAŞLIĞI; DERGİ ADI; CİLT/SAYI/SAYFA; TARİH,

MAKALE ADRESİ

1 SCI,

SCIE

Jones EA, Yurdaydın C. (Editorial) Is fatigue associated with cholestasis mediated by

altered central neurotransmission? Hepatology 1997; 25: 492-4

2 SCI,

SCIE

Yurdaydin C. Blood ammonia determination in cirrhosis: Still confusing after all these

years ?. Hepatology 2003; 38:1307-1310

3 SCIE Yurdaydın C. Delta hepatitis in Turkey: Decreasing but not vanishing and still of concern.

Turk J Gastroenterol 2006; 17:74-5

4 SCIE Karaaslan H, Yurdaydin C. Viral hepatitis at the Black Sea region: the problem of viral

hepatitis in Turkey revisited. Turk J Gastroenterol. 2009; 20:1-2.

5

SCI,

SCIE

Yurdaydin C, Akarca US. Treatment of chronic hepatitis B with telbivudine: wise

hepatologists needed in hepatitis B endemic countries where treatment options are

limited.Liver Int. 2011 May;31(5):589-91.

6

SCI,

SCIE

Kutlu T, Soycan LY, Karatayli E, Turkyilmaz AR, Yurdaydin C, Bozdayi AM. The first

identified hepatitis B virus vaccine escape mutation in Turkey. J Clin Virol 2006; 35:201-

2








15

7

SCI Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, Gines P, Kim WR,

Kamath PS; World Gastroenterology Organization Working Party. Toward an improved

definition of acute-on-chronic liver failure.Gastroenterology. 2014 Jul;147(1):4-10. doi:

10.1053/j.gastro.2014.05.005. Epub 2014 May 20.

ULUSLARASI KONGRELERDE SUNULMUŞ VE SCI KAPSAMLI DERGİLERDE ÖZETİ

YAYINLANMIŞ BİLDİRİLER

NO

1

SCI

NO EVIDENCE FOR INCREASED SEROTONINERGIC ACTIVITY IN HEPATIC-

ENCEPHALOPATHY IN THIOACETAMIDE-INDUCED ACUTE LIVER-FAILURE

IN RATS. By: YURDAYDIN, C; PIFL, C; HORTNAGL, H; et al.

HEPATOLOGY Volume: 8 Issue: 5 Pages: 1351-1351 Published: SEP-OCT 1988

2

SCI

MODULATION OF HEPATIC-ENCEPHALOPATHY (HE) BY BENZODIAZEPINE

RECEPTOR (BZR) LIGANDS IS SELECTIVE

By: YURDAYDIN, C; FROMM, C; HOLT, AG; et al.

HEPATOLOGY Volume: 14 Issue: 4 Pages: A89-A89 Part: 2 Published: OCT 1991

3

SCI

IS THE OPIOID SYSTEM IMPLICATED IN HEPATIC-ENCEPHALOPATHY

By: YURDAYDIN, C; ROTHMANN, RB; VERGALLA, J; et al.


4

SCI

EFFICACY OF BENZODIAZEPINE RECEPTOR (BZR) ANTAGONISTS IN

IMPROVING HEPATIC-ENCEPHALOPATHY (HE) MAY BE RELATED TO THEIR

AFFINITY FOR DIAZEPAM INSENSITIVE RECEPTORS

By: YURDAYDIN, C; WONG, G; BASILE, AS; et al.


5

SCI

NALOXONE AMELIORATES THE PRURITUS OF CHOLESTASIS - RESULTS OF A

DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL

By: BERGASA, NV; ALLING, DW; TALBOT, TL; et al.

HEPATOLOGY Volume: 16 Issue: 4 Pages: A152-A152 Part: 2 Published: OCT

1992

6

SCI

THE ROLE OF GUT BACTERIA IN THE ACCUMULATION OF BENZODIAZEPINE

RECEPTOR (BZR) LIGANDS IN HEPATIC-ENCEPHALOPATHY (HE)

By: YURDAYDIN, C; ENGLER, H; LI, Y; et al.

GASTROENTEROLOGY Volume: 104 Issue: 4 Supplement: S Pages: A1022-

A1022 Published: APR 1993

7

EVIDENCE FOR AN INCREASED SEROTONINERGIC TONE IN EXPERIMENTAL

HEPATIC-ENCEPHALOPATHY IN THE RAT



http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=C1jjvFuRA8CPO6DI1Nv&page=22&doc=216&cacheurlFromRightClick=no









http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=C1jjvFuRA8CPO6DI1Nv&page=22&doc=212






16

SCI By: HERNETH, AM; PUSPOK, A; STEINDL, P; et al.



8

SCI

RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF

RIBAVIRIN THERAPY FOR CHRONIC HEPATITIS-C

By: DIBISCEGLIE, AM; FRIED, MW; SWAIN, MG; et al.


9

SCI

NALMEFENE THERAPY IS ASSOCIATED WITH THE RELIEF OF THE PRURITUS

OF CHOLESTASIS - RESULTS OF A DOUBLE-BLIND RANDOMIZED PLACEBO-

CONTROLLED TRIAL

By: BERGASA, NV; ALLING, DW; TALBOT, TL; et al.


1993

10

SCI

ORNITHINE DECARBOXYLASE INHIBITION IS ASSOCIATED WITH

INCREASED SURVIVAL IN THIOACETAMIDE-INDUCED HEPATITIS

By: YURDAYDIN, C; SWAIN, M; VERGALLA, J; et al.



11

SCI

BENZODIAZEPINE RECEPTOR LIGANDS (BRL) ARE SYNTHESIZED DE-NOVO

IN THE BRAIN

By: YURDAYDIN, C; ENGLER, H; WALSH, TJ; et al.


1994

12

SCI

HOW IMPORTANT IS THE INTRINSIC ACTIVITY OF BENZODIAZEPINE

RECEPTOR (BZR) LIGANDS IN THE BEHAVIORAL AMELIORATION OF

HEPATIC-ENCEPHALOPATHY (HE)

By: CETINKAYA, H; YURDAYDIN, C; PALAOGLU, O; et al.


1994

13

SCI

HEPATIC INVOLVEMENT IN BRUCELLOSIS - A RETROSPECTIVE ANALYSIS

By: KARAYELIOGLU, D; KILIC, D; TEKELI, ME; et al.

HEPATOLOGY Volume: 22 Issue: 4 Supplement: S Pages: 1320-

1320 Part: 2 Published: OCT 1995

14

SCI

Mutations in the core promoter region of HBV are not responsible for HBeAg (-)

phenotype in Turkish patients with chronic HBV infection.

By: Bozkaya, H; Uzunalimoglu, O; Cetinkaya, H; et al.


















17

15

SCI

Hepatitis C virus, lichen planus and Behcet's disease.

By: Uzunalimoglu, O; Yurdaydin, C; Bozkaya, H; et al.



16

SCI

High prevalence of diabetes mellitus in patients with chronic hepatitis C infection

By: Uzunalimoglu, O; Cetinkaya, H; Sipahi, N; et al.



17

SCI

Opioid ligands in human hepatic encephalopathy.

By: Yurdaydin, C; Karavelioglu, D; Yasa, H; et al.



18

SCI

Prevalence of a positive pathergy test in patients with chronic HCV infection

By: Uzunalimoglu, O; Cetinkaya, H; Bozkaya, H; et al.



19

SCI

Combination treatment of thioacetamide (TAA)-induced fulminant hepatic failure in the

rat with benzodiazepine- and opioid receptor antagonists.

By: Celik, T; Uzbay, IT; Uzunalimoglu, O; et al.



20

SCI

TH1/TH2 cytokines and their relations to HBeAg status and ALT flares in chronic HBV

infection.

By: Bozkaya, H; Bozdayi, AM; Turkyilmaz, A; et al.

HEPATOLOGY Volume: 28 Issue: 4 Supplement: S Pages: 721A-

721A Part: 2 Meeting Abstract: 2233 Published: OCT 1998

21

SCI

Possible mechanisms of the hepatoprotective effect of difluoromethylornithine (DFMO)

on thioacetamide (TAA)-induced fulminant hepatic failure in the rat.

By: Cinar, K; Bozdayi, M; Bozkaya, H; et al.



22

SCI

N-acetylcysteine in thioacetamide induced toxic hepatitis in rats.

By: Uzunalimoglu, O; Cinar, K; Erekul, S; et al.



23

SCI

Cytokine production during interferon treatment in patients with chronic hepatitis C.

By: Bozkaya, H; Bozdayi, AM; Arslan, N; et al.














18


24

SCI

Are mutations in ISDR of NS5A gene related with response to IFN in Turkish patients

with chronic hepatitis C virus 1b infection?.

By: Aslan, N; Bozdayi, AM; Cetinkaya, H; et al.



25

SCI

Treatment of chronic hepatitis D with famciclovir: A pilot study

By: Yurdaydin, C; Bozkaya, H; Gurel, S; et al.

JOURNAL OF HEPATOLOGY Volume: 32 Supplement: 2 Pages: 116-

116 Published: 2000

26

SCI

Low level hepatocyte proliferation and high viral load are associated with nuclear

localization of hepatitis B core antigen (HBcAg)

By: Bozkaya, H; Erden, E; Varh, M; et al.


116 Published: 2000

27

SCI

Is it possible to decrease at one year the lamivudine treatment induced serum HBV-DNA

breakthrough rates?

By: Karayalcin, S; Yurdaydin, C; Bozdayi, AM; et al.

GASTROENTEROLOGY Volume: 118 Issue: 4 Supplement: 2 Pages: A1004-

A1004 Part: 1 Meeting Abstract: 2348 Published: APR 2000

28

SCI

Treatment of HBeAg (-) chronic hepatitis B with lamivudine vs. lamivudine plus

interferon: A randomized controlled clinical trial

By: Yurdaydin, C; Bozkaya, H; Cetinkaya, H; et al.


163 Published: APR 2001

29

SCI

Comparision of two different primer sets for PCR detection of transfusion transmitted

virus DNA in blood donors, hemodialysis patients and patients with thalassemia major,

chronic HBV and HCV infection

By: Verdi, H; Uzunalimoglu, O; Cagsin, S; et al.



30

SCI

Frequent occurance of lamivudine resistant mutants in HBeAg (+) but not in HBeAg (-)

patients with chronic hepatitis B

By: Bozkaya, H; Yurdaydin, C; Bozdayi, AM; et al.



31

SCI

A new mutation pattern (YMDD -> YSDD) in YMDD motif of HBV-DNA polymerase

gene in chronic B hepatitis infection resistant to lamivudine treatment

By: Bozdayi, AM; Uzunalimoglu, O; Turkyilmaz, AR; et al.

















19



32

SCI

Thrombophilic gene mutations in cirrhosis with portal vein thrombosis

By: Erkan, O; Bozdayi, AM; Bozbas, A; et al.



33

SCI

Lamivudine is not effective in the treatment of non-cirrhotic HBeAg(-) chronic hepatitis B

(CHB) patients with low level viremia.

By: Bozkaya, H; Bozdayi, MA; Yurdaydin, C; et al.



33

SCI

Is fatigue of cholestasis mediated by altered central serotoninergic neurotransmission?.

By: Yurdaydin, C; Celik, T; Goren, ZM; et al.



34

SCI

Screening for hemochromatosis in Turkey

By: Bektas, M; Metin, O; Erkan, O; et al.

JOURNAL OF HEPATOLOGY Volume: 36 Supplement: 1 Pages: 254-255 Meeting

Abstract: 916 Published: APR 2002

35

SCI

Long term follow up chronic hepatitis B patients treated with interferon

By: Cetinkaya, H; Uzunalimoglu, O; Sarioglu, M; et al.



36

SCI

Ganciclovir treatment of lamivudine-resistant HBV infection

By: Bozkaya, H; Yurdaydin, C; Karayalcin, S; et al.



37

SCI

Phenotype-genotype correlations in patients with Wilson disease (WD)

By: Ferenci, P; Polli, C; Smolarek, C; et al.



38

SCI

Predictive value of ALT and HBV DNA levels in response to sequential combination

treatment of lamivudine and interferon in HBeAg-/anti-HBe plus chronic hepatitis B

By: Cinar, K; Sarioglu, M; Cetinkaya, H; et al.



39

SCI

Lamivudine is not effective in the treatment of pion-cirrhotic HBeAg (-) chronic hepatitis

B patients with low level viremia

By: Bozkaya, H; Yurdaydin, C; Bozdayi, M; et al.













20



40

SCI

Is fatigue of cholestasis mediated by altered central serotoninergic neurotransmission?

By: Celik, T; Aslan, N; Goren, Z; et al.



41

SCI

Treatment of human hepatic encephalopathy with the opioid receptor antagonist naloxone.

By: Gokturk, S; Deda, G; Bozkaya, H; et al.

Conference: 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases

(AASLD) Location: BOSTON, MASSACHUSETTS Date: NOV 01-05, 2002

Sponsor(s): Amer Assoc Study Liver Dis



42

SCI

The hepaxoprotective effect of difluorometrylornithine: Studies in rat models of fulminant

hepatic failure.

By: Cinar, K; Celik, T; Bozkaya, H; et al.

Conference: 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases

(AASLD) Location: BOSTON, MASSACHUSETTS Date: NOV 01-05, 2002




43

SCI

Clinical and demographic characteristics of patients with non-alcoholic steatohepatitis: A

multicenter study

By: Sarioglu, M; Akarca, U; Sonsuz, A; et al.

Conference: 38th Annual Meeting of the European-Association-for-the-Study-of-the-

Liver Location: ISTANBUL, TURKEY Date: MAR 29-APR 01, 2003

Sponsor(s): European Assoc Study Liver



44

SCI

Two year interferon treatment of chronic delta hepatitis

By: Yurdaydin, C; Bozkaya, H; Erkan, O; et al.






45

SCI

L180C: A novel mutation pattern selected during lamivudine treatment of chronic

hepatitis B infection

By: Bozdayi, AM; Turkyilmaz, AR; Sarioglu, M; et al.














21


46

SCI

Hepatitis B virus genotypes and subtypes, hepatitis C virus genotypes and hepatitis delta

virus types in Turkish patients with hepatitis virus infections

By: Bozdayi, AM; Aslan, N; Bozdayi, G; et al.






47

SCI

Genetic variability of hepatitis delta virus in Turkish and German patients: Implications

for cellular immune responses

By: Aslan, N; Yurdaydin, C; Bozkaya, H; et al.






48

SCI

Peroxisome proliferator activated receptor-alpha (PPAR-alpha) expression is induced but

peroxisomal enzyme response to clofibrate is blunted in a rat model of fatty liver

By: Akbiyik, F; Cinar, K; Ozsullu, T; et al.






49

SCI

Analysis and function of delta-hepatitis virus-specific cellular immune responses

By: Aslan, N; Yurdaydin, C; Bozkaya, H; et al.






50

SCI

A phase III, partially double-blinded study evaluating the efficacy and safety of

peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine

vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis

B.

By: Marcellin, P; Lau, GKK; Bonino, F; et al.

Conference: 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-

Disease Location: BOSTON, MASSACHUSETTS Date: OCT 24-28, 2003

Sponsor(s): Amer Assoc Study Liver Diseases

HEPATOLOGY Volume: 38 Issue: 4 Supplement: 1 Pages: 724A-725A Meeting

Abstract: 1181 Published: OCT 2003

51

SCI

Phenotype-genotype correlations in patients with Wilson disease (WD).

By: Ferenci, P; Schafer, M; Szalay, F; et al.


Diseases Location: BOSTON, MA Date: OCT 24-28, 2003













22




52

SCI

Recipient-derived hepatocytes in sex-mismatched living-related partial liver transplants.

By: Idilman, R; Erden, E; Kuzu, I; et al.


Disease Location: BOSTON, MASSACHUSETTS Date: OCT 24-28, 2003

Sponsor(s): Amer Assoc Study Liver Diseases



53

SCI

Mutation analysis in Turkish patients with Wilson disease

By: Yurdaydin, C; Demir, K; Bozkaya, H; et al.


Liver Location: Berlin, GERMANY Date: APR 14-18, 2004




54

SCI

Cytotoxic CD4+ T cells in viral hepatitis

By: Aslan, N; Yurdaydin, C; Tillmann, HL; et al.






55

SCI

Comparison of liver functional parameters with serum fibrosis markers as predictors of

severe necro-inflammation in patients with chronic hepatitis B and D

By: Yurdaydin, C; Toruner, M; Bozkaya, H; et al.






56

SCI

Recipient-derived hepatocytes in sex-mismatched liver allograft after liver transplantation

By: Idilman, R; Erden, E; Kuzu, I; et al.






57

SCI

PPAR-alpha L162V polymorphism in human hepatocellular carcinoma

By: Koytak, ES; Verdi, H; Akbiyik, F; et al.

Conference: Digestive Disease Week/105th Annual Meeting of the American-

Gastroenterological-AssociationLocation: New Orleans, LA Date: MAY 16-19, 2004

Sponsor(s): Amer Gastroenterol Assoc








23



58

SCI

In vivo and in vitro hepatocyte expression of peroxisome proliferator activated receptor-

alpha (PPARa) by PPARa ligands

By: Akbiyik, F; Cinar, K; Demirpence, E; et al.

Conference: Digestive Disease Week/105th Annual Meeting of the American-

Gastroenterological-AssociationLocation: New Orleans, LA Date: MAY 16-19, 2004

Sponsor(s): Amer Gastroenterol Assoc



59

SCI

Comprehensive analysis of HDV-specific CD4+ and CD8+ T cell responses

By: Aslan, N; Yurdaydin, C; Ciner, A; et al.


Diseases (AASLD)Location: Boston, MA Date: OCT 29-NOV 02, 2004


HEPATOLOGY Volume: 40 Issue: 4 Supplement: 1 Pages: 719A-

719A Published: OCT 2004

60

SCI

Better safety and quality of life in patients with chronic hepatitis B than in patients with

chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS (R))

monotherapy

By: Marcellin, P; Lau, G; Piratvisuth, T; et al.






61

SCI

Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory,

HBeAg(+) chronic hepatitis B: Results of phase III study ETV-026

By: Sherman, M; Yurdaydin, C; Sollano, J; et al.

Group Author(s): BEHoLD Study Grp






62

SCI

First detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B:

Data from a multicenter, randomized, partially double-blind study of peginterferon alfa-2a

(40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine alone

By: Bonino, F; Lau, G; Marcellin, P; et al.


















24

63

SCI

ALT flares and sustained ALT response in patients with HBeAg-negative chronic

hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS (R)), peginterferon alfa-

2a (40KD) plus lamivudine or lamivudine alone

By: Piratvisuth, T; Marcellin, P; Lau, G; et al.






64

SCI

Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS

(R)) plus lamivudine combination therapy limits the development of YMDD mutations,

but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone

By: Germanidis, G; Marcellin, P; Lau, G; et al.






65

SCI

PPAR-alpha L162V polymorphism in nonalcoholic steatohepatitis.

By: Verdi, H; Koytak, ES; Ergul, AA; et al.






66

SCI

Phenotype-genotype correlations in siblings of index patients with Wilson disease (WD).

By: Ferenci, P; Caca, K; Stremmel, W; et al.






67

SCI

Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory,

HBeAg(+) chronic hepatitis B: results of Phase III study ETV-026

By: Sherman, M; Yurdaydin, C; Sollano, J; et al.


Conference: 6th International Workshop on Adverse Drug Reactions and Lipodystrophy

in HIV Location: Washington, DC Date: OCT 25-28, 2004

ANTIVIRAL THERAPY Volume: 9 Issue: 6 Pages: H22-H23 Published: DEC 2004

68

SCI

Lamivudine-refractory, chronic hepatitis B patients can be safely switched to entecavir 1.0

mg daily without risk of ALT flare

By: Boyer, T; Sherman, M; Yurdaydin, C; et al.


Conference: 6th International Workshop on Adverse Drug Reactions and Lipodystrophy

in HIV Location: Washington, DC Date: OCT 25-28, 2004













25

ANTIVIRAL THERAPY Volume: 9 Issue: 6 Pages: H20-H20 Published: DEC 2004

69

SCI

Potential role of cytokine gene polymorphisms in hepatitis B infection outcome

By: Arslan-Ergul, A; Yurdaydin, C; Koytak, ES; et al.


Liver Location: Paris, FRANCE Date: APR 13-17, 2005



70

SCI

Alanine aminotransferase (ALT) flares are uncommon both on- and post-treatment in

entecavir treated HBeAg(+) patients

By: Yurdaydin, C; Gish, RG; Chang, TT; et al.





71

SCI

Entecavir (ETV) demonstrates consistent responses throughout baseline demographic

subgroups for the treatment of nucleosidenaive, HBeAg(+) and HBeAg(-) patients with

chronic hepatitis B

By: Shouval, D; Senturk, H; Gish, RG; et al.





72

SCI

Sustained response to peginterferon alpha-2a(40kDa) (Pegasys (R)) in HBeAg-negative

chronic hepatitis B. 1-year follow-up data from a large, randomised multinational study

By: Marcellin, P; Lau, GKK; Bonino, F; et al.





73

SCI

Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory

chronic hepatitis B: Phase II/II safety results

By: Manns, MP; Raptopoulou-Gigi, M; Sollano, J; et al.





74

SCI

The efficacy of entecavir is similar regardless of disease-related baseline subgroups in

treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B

By: Lurie, Y; Manns, MP; Gish, RG; et al.





75

On-treatment predictors of sustained biochemical and virological response in patients with















26

SCI

HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon alpha-2a (40 kDa)

(Pegasys (R))

By: Farci, P; Marcellin, P; Lu, ZM; et al.





76

SCI

Alanine aminotransferase (ALT) flares are less frequent with entecavir than lamivudine

treatment both on- and off-treatment in HBeAg(+) patients

By: Tsai, N; Han, SHB; Sherman, M; et al.

Conference: Annual Meeting of the American-Gastroenterological-Association/Digestive-

Disease-Week Location: Chicago, IL Date: MAY 14-19, 2005

Sponsor(s): Amer Gastroenterolog Assoc



77

SCI

Entecavir demonstrates consistent responses among baseline subgroups in the treatment of

nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B

By: Brown, RS; Lok, AS; Gish, RG; et al.

Conference: Annual Meeting of the American-Gastroenterological-Association/Digestive-

Disease-Week Location: Chicago, IL Date: MAY 14-19, 2005

Sponsor(s): Amer Gastroenterolog Assoc



78

SCI

Treatment of chronic hepatitis D (CHD) with interferon vs. interferon plus lamivudine vs.

lamivudine: Short-and long-term results

By: Yurdaydin, C; Bozkaya, H; Onder, O; et al.


Diseases Location: San Francisco, CA Date: NOV 11-15, 2005




79

SCI

Factors associated with sustained virologic response 1 year after treatment with

peginterferon alfa-2A (40KD) (PEGASYS (R)) monotherapy for HBEAG-negative

chronic hepatitis B

By: Marcellin, P; Bonino, F; Lau, GY; et al.






80

SCI

Bacterial translocation in cirrhotic rats: Therapeutic role of INOS inhibitor S-methyl

isothiourea

By: Yilmaz, S; Uzunalimoglu, O; Mas, MR; et al.
















27





81

SCI

Phenotype-genotype correlations Wilson disease (WD) - Results of a multinational study

in 1008 patients

By: Ferenci, P; Merle, U; Folhoffer, A; et al.






82

SCI

Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the HEP-

NET/International HDV Intervention Trial

By: Zachou, K.; Yurdaydin, C.; Dienes, H. R.; et al.

Conference: 41st Annual Meeting of the European-Association-for-the-Study-of-the-

Liver Location: Vienna, AUSTRIA Date: APR 26-30, 2006


JOURNAL OF HEPATOLOGY Volume: 44 Supplement: 2 Pages: S178-

S178 Meeting Abstract: 479 Published: 2006

83

SCI

Entecavir results in continued virologic and biochemical improvement and HBeAg

seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+)

chronic hepatitis B patients (ETV-026)

By: Yurdaydin, C.; Sollano, J.; Hadziyannis, S.; et al.




JOURNAL OF HEPATOLOGY Volume: 44 Supplement: 2 Pages: S36-S36 Meeting

Abstract: 80 Published: 2006

84

SCI

Entecavir (ETV) demonstrates consistent responses throughout baseline disease and

demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients

with chronic hepatitis B

By: Yurdaydin, C.; Senturk, H.; Boron-Kaczmarska, A.; et al.






85

SCI

Inhibition of hepatitis B virus replication by shRNA in stably HBV expressing HEPG

2.2.15 cell lines

By: Kayhan, H.; Karatayli, E.; Turkyilmaz, A. R.; et al.



















28

86

SCI

A novel mutation pattern developed during lamivudine treatment shows cross-resistance

to adefovir dipivoxil treatment

By: Karatayli, E.; Karayalcin, S.; Kayhan, H.; et al.






87

SCI

Retreatment with peginterferon alpha-2a (40KD) (PEGASYS (R)) plus ribavirin

(COPEGUS (R)) in pegylated interferon alpha-2b (12KD)/ribavirin non-responders with

cirrhosis/advanced fibrosis: Repeat interim analysis

By: Gitlin, N.; Jensen, D.; Di Bisceglie, A.; et al.






88

SCI

Alanine aminotransferase (ALT) as an alternative to HBV DNA as a marker of sustained

response to peginterferon alfa-2a (40 KD) (PEGASYS) treatment

By: Piratvisuth, Teerha; Lau, George K. K.; Lu, Zhi-Meng; et al.

JOURNAL OF GASTROENTEROLOGY AND

HEPATOLOGY Volume: 21 Supplement: 2 Pages: A108-A109 Published: MAR

2006

89

SCI


Seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+)


By: Sherman, Morris; Martin, Paul; Lee, William M.; et al.

Conference: Digestive Disease Week Meeting/107th Annual Meeting of the American-

Gastroenterlogical-Association Location: Los Angeles, CA Date: MAY 20-25, 2006

Sponsor(s): Amer Gastroenterlog Assoc Inst



90

SCI

Late onset Wilson disease (WD)

By: Ferenci, Peter; Szalay, Ferenc; Uta, Merle; et al.

Conference: Digestive Disease Week Meeting/107th Annual Meeting of the American-

Gastroenterlogical-Association Location: Los Angeles, CA Date: MAY 20-25, 2006

Sponsor(s): Amer Gastroenterlog Assoc Inst



91


seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+)



















29

SCI By: Yurdaydin, C.; Sollano, J.; Hadziyannis, S.; et al.

Conference: 12th International Symposium on Viral Hepatitis and Liver

Disease Location: Paris, FRANCE Date: JUL 01-05, 2006

Sponsor(s): Pan-Amer Soc Clin Virol; European Soc Clin Virol

JOURNAL OF CLINICAL VIROLOGY Volume: 36 Supplement: 2 Pages: S55-

S55 Published: JUL 2006

92

SCI

Response is sustained two years post-treatment in the majority of patients with HBeAg-

negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)]

By: Marcellin, P.; Bonino, F.; Lau, G. K. K.; et al.

Conference: 12th International Symposium on Viral Hepatitis and Liver

Disease Location: Paris, FRANCE Date: JUL 01-05, 2006

Sponsor(s): Pan-Amer Soc Clin Virol; European Soc Clin Virol

JOURNAL OF CLINICAL VIROLOGY Volume: 36 Supplement: 2 Pages: S95-

S96 Published: JUL 2006

93

SCI

Entecavir (ETV) results in continued virologic and biochemical improvement through 96

weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients

(ETV-026)

By: Yurdaydin, C.; Sollano, J.; Hadziyannis, S.; et al.

LIVER INTERNATIONAL Volume: 26 Supplement: 1 Pages: 14-

14 Published: OCT 2006

94

SCI

Potential role of cytokine gene polymorphisms in outcome of chronic delta hepatitis

By: Ulger, Zeynep; Emir, Filiz; Arslan-Ergul, Ayca; et al.


Diseases Location: Boston, MA Date: OCT 27-31, 2006




95

SCI

Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated

interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in

hdvcoinfected patients with low HBV viremia

By: Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; et al.






96

SCI

Suppression of HBV DNA in patients with HBeAg-negative CHB treated with

peginterferon alfa-2A (40KD) +/- lamivudine: 2-year follow-up results

By: Marcellin, Patrick; Bonino, Ferruccio; Lau, George K.; et al.



















30

97

SCI

Significant reduction of HBsAg in the sera of HBeAg-negative chronic hepatitis B

patients treated with peginterferon alfa-2A alone or in combination with lamivudine

By: Brunetto, Maurizia; Bonino, Ferruccio; Moriconi, Francesco; et al.






98

SCI

The hepatoprotective effect of difluoromethylornithine in thioacetamide-induced

fulminant hepatic failure may be due to methionine

By: Onder, Oguz F.; Cinar, Kubilay; Celik, Turgay; et al.






99

SCI

A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a

plus adevofir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adevofir dipivoxil

for the treatment of chronic delta hepatitis: The hep-net/international delta hepatitis

intervention trial (HID-IT)

By: Yurdaydin, Cihan; Wedemeyer, Heiner; Dalekos, George; et al.






100

SCI

72 week data of the HIDIT-1 trial: A multicenter randomised study comparing

peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir

in chronic delta hepatitis

By: Wedemeyer, H.; Yurdaydin, C.; Dalekos, G.; et al.


Liver Location: Barcelona, SPAIN Date: APR 11-15, 2007




101

SCI

Differential cytokine pattern of HDV-specific cellular immune responses distinguishes

treatment responder and nonresponder to peg-IFN alpha-2a treatment: Results from the

HEP-NET/international HIDIT-1 study

By: Wedemeyer, H.; Ciner, A.; Yurdaydin, C.; et al.






102 TNF-alpha mediates the ethanol induced PPAR-alpha supression in the liver

By: Onder, F. O.; Sengul, S.; Calayoglu, R.; et al.
















31

SCI






103

SCI

Virological and biochemical response in patients with hbeag-negative CHB treated with

peginterferon alpha-2a (40KD) lamivudine: 3-year follow-up results

By: Marcellin, P.; Bonino, F.; Lau, G. K.; et al.






104

SCI

High baseline HBV-DNA is linked to the emergence of adefovir resistance in lamivudine

resistant patients

By: Kaymakoglu, S.; Idilman, R.; Ahishali, E.; et al.






105

SCI

Predictors of HBsAg reduction in HBsAg-negative chronic hepatitis B patients treated

with peginterferon a-2a (40 kD) alone or in combination with lamivudine

By: Brunetto, M.; Bonino, F.; Moricomi, F.; et al.






106

SCI

Complete genome sequences and phylogenetic analysis of hepatitis D viruses (HDV)

isolated from turkish patients with chronic HDV infection

By: Emir, Filiz; Bektas, Mehmet; Kesen, Ela; et al.


Diseases Location: Boston, MA Date: NOV 02-06, 2007


HEPATOLOGY Volume: 46 Issue: 4 Supplement: S Pages: 894A-894A Meeting


107

SCI

Long-term follow-up of HBsAg clearance in patients with HBeAg-negative CHB treated

with Peginterferon alfa-2a: Increase in HBsAg, clearance rate from 3% 6 months post-

treatment to 8% after 3 years

By: Marcellin, Patrick; Brunetto, Maurizia; Bonino, Ferruccio; et al.
















32


108

SCI

Drug susceptibility testing of a novel mutation pattern (A181S+M204I) conferring

resistance to lamivudine and adefovir dipivoxil

By: Karatayli, Ersin; Karayalcin, Selim; Karaaslan, Hayri; et al.






109

SCI

Hdv-specific IP-10 responses but not IP-10 serum levels correlate with response to PEG-

IFNA-2a treatment of delta hepatitis: Results from the HEP-NEV/international HIDIT-1

study

By: Wedemeyer, Heiner; Yurdaydin, Cihan; Ciner, Ayse; et al.






110

SCI

Adefovir treatment of entecavir resistance in patients with lamivudine-refractory chronic

hepatitis B

By: Yurdaydin, C.; Idilman, R.; Cevik, E.; et al.

Conference: 43rd Annual Meeting of the European-Association-for-the-Study-of-the-

Liver Location: Milan, ITALYDate: APR 23-27, 2008




111

SCI

Serum cytokine levels during PEG-IFNa-2a+/- adefovir treatment of delta hepatitis:

Results from the hep-net/international HIDIT-1 study

By: Wedemeyer, H.; Yurdaydin, C.; Zachou, K.; et al.






112

SCI

Virological and biochemical response in patients with HBeAG-negative chronic hepatitis

B treated with peginterferon alfa-2a (40KD) with or without lamivudine: Results of 4-year

follow-up

By: Marcellin, P.; Piratvisuth, T.; Brunetto, M.; et al.






113

HBV DNA suppression induced by peginterferon alfa-2a (40kd) but not by lamivudine















33

SCI

results in HBsAg loss and seroconversion at 3 years post-treatment

By: Brunetto, M.; Bonino, E.; Marcellin, P.; et al.






114

SCI

On-treatment HBsAg decline in HBeAg-negative patients as a predictor of response to

peginterferon alfa-2a (40kd) therapy 3 years post-treatment: Potential for response-guided

therapy

By: Brunetto, M.; Bonino, E.; Lau, G. K. K.; et al.






115

SCI

HBEAG-POSITIVE DELTA HEPATITIS: VIROLOGICAL; BIOCHEMICAL AND

CLINICAL FEATURES IN A LARGE EUROPEAN MULTICENTER DATA BASE

By: Heidrich, Benjamin; Wedemeyer, Heiner; Bektas, Mehmet; et al.


Diseases Location: San Francisco, CA Date: OCT 31-NOV 04, 2008

Sponsor(s): Amer Assoc Study Liver Dis; Moscone West Convent Ctr



116

SCI

TREATMENT OF HBEAG-POSITIVE CHRONIC DELTA HEPATITIS WITH

NUCLEOS(T)IDE ANALOGS

By: Yurdaydin, Cihan; Bozkaya, Hakon; Heidrich, Benjamin; et al.






117

SCI

BASELINE ALT LEVELS BUT NOT HDV-RNA LEVELS ARE ASSOCIATED WITH

RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT OF DELTA

HEPATITIS: DATA FROM THE HIDIT-1 TRIAL

By: Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; et al.






118

SCI

DRUG INDUCED LIVER INJURY: A SINGLE CENTER EXPERIENCE OVER A 7-

YEAR PERIOD

By: Bektas, Mehmet; Idilmon, Romazon; Cerit, Turgay; et al.















34





119

SCI

INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN

PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH

PEGINTERFERON ALFA-2A +/- LAMIVUDINE: RESULTS OF 5-YEAR POST-

TREATMENT FOLLOW UP

By: Marcellin, P.; Piratvisuth, T.; Brunetto, M.; et al.


Liver Location: Copenhagen, DENMARK Date: APR 22-26, 2009




120

SCI

POTENTIAL PROTEOMIC BIOMARKERS IN ASSESSING LIVER FIBROSIS

USING SELDI-TOF MS

By: Karatayli, S. C. Ozen; Mizrak, D.; Sayki, M.; et al.


Liver Location: Copenhagen, DENMARK Date: APR 22-26, 2009


JOURNAL OF HEPATOLOGY Volume: 50 Pages: S112-S112 Meeting


121

SCI

COMPARATIVE ASSESSMENT OF TURKEY'S IMPACT ON HEPATOCELLULAR

CARCINOMA RESEARCH

By: Yazihan, Nuray; Yilmaz, Hakki H.; Tuncer, Murat; et al.


Diseases Location: Boston, MA Date: OCT 30-NOV 03, 2009


HEPATOLOGY Volume: 50 Issue: 4 Pages: 1130A-1130A Meeting


122

SCI

THE BURDEN OF DELTA HEPATITIS PROJECTED USING A MATHEMATICAL

MODEL IN A DELTA HEPATITIS ENDEMIC COUNTRY

By: Toy, Mehlika; Onder, Fatih Oguz; Idilman, Ramazan; et al.






123

SCI

PROTEOMIC BIOMARKERS IN ASSESSMENT OF LIVER FIBROSIS USING

SELDI-TOF MS

By: Karatayli, Senem C.; Mizrak, Dilsa; Arslan, Muyesser; et al.
















35



124

SCI

EFFICACY OF PEGYLATED INTERFERON-BASED TREATMENT IN PATIENTS

WITH CIRRHOSIS DUE TO CHRONIC DELTA HEPATITIS: COMPARISON WITH

NON-CIRRHOTIC PATIENTS

By: Yurdaydin, Cihan; Kobacam, Gokhan; Cakaloglu, Yilmaz; et al.






125

SCI

ENTECAVIR MAY BE BENEFICIAL IN A SUBSET OF PATIENTS WITH CHRONIC

DELTA HEPATITIS

By: Onder, Fatih Oguz; Yakut, Mustafa; Idilman, Ramazan; et al.






126

SCI

CLONAL ANALYSIS OF THE QUASISPECIES OF ANTIVIRAL RESISTANT HBV

GENOMES IN PATIENTS WITH ENTECAVIR RESISTANCE TREATED WITH

RESCUE LAMIVUDINE-ADEFOVIR COMBINATION THERAPY

By: Karatayli, Ersin; Idilman, Ramazan; Karatayli, Senem C.; et al.






127

SCI

THE BURDEN OF CHRONIC HEPATITIS B IN A MEDIAN ENDEMIC COUNTRY:

A MATHEMATICAL APPROACH

By: Toy, Mehlika; Onder, Fatih Oguz; Idilman, Ramazan; et al.






128

SCI

A FINITE COURSE OF PEGINTERFERON ALFA-2A RESULTS IN INACTIVE

CHRONIC HEPATITIS B AND HBSAG CLEARANCE 5 YEARS POST-

TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE DISEASE: BASELINE

CHARACTERISTICS AND PREDICTIVE FACTORS OF LONG-TERM RESPONSE

By: Marcellin, Patrick; Piratvisuth, Teerha; Brunetto, Maurizia R.; et al.

















36





129

SCI

THERAPEUTIC EFFICACY OF L-ORNITHINE-L-ASPARTATE INFUSIONS IN

PATIENTS WITH CIRRHOSIS AND HEPATIC ENCEPHALOPATHY

By: Oruc, N.; Ozturk, A.; Onal, I. K.; et al.





S79 Published: 2010

130

SCI

ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS

WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON

ALFA-2A TREATMENT

By: Mederacke, I.; Yurdaydin, C.; Bremer, B.; et al.





S135 Published: 2010

131

SCI

OUTCOME AND VIROLOGICAL CHANGES DURING THE FOLLOW UP OF A

LARGE SINGLE CENTER COHORT OF CHRONIC DELTA HEPATITIS PATIENTS

By: Kabacam, G.; Oender, F. O.; Seven, G.; et al.





S133 Published: 2010

132

SCI

EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN

FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737

PATIENTS WITH CHRONIC HEPATITIS B

By: Lampertico, Pietro; Vigano, Mauro; Yurdaydin, Cihan; et al.

Conference: 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-




Abstract: 369

133

SCI

CHARACTERIZATION OF THE INACTIVE HBSAG CARRIER STATE

By: Yakut, Mustafa; Bektas, Mehmet; Seven, Gulseren; et al.
















37


134

SCI

THE COST-EFFECTIVENESS OF TREATING ELIGIBLE CHRONIC HEPATITIS B

AND CIRRHOTIC PATIENTS IN A MEDIAN ENDEMIC COUNTRY

By: Toy, Mehlika; Onder, Fatih Oguz; Richardus, Jan Hendrik; et al.






135

SCI

CLEVUDINE TREATMENT OF CHRONIC DELTA HEPATITIS

By: Yakut, Mustafa; Seven, Gulseren; Baran, Bulent; et al.






136

SCI HBSAG SEROCOVERSION UNDER LAMIVUDINE IN HBEAG-NEGATIVE

CHRONIC HEPATITIS B

By: Seven, Gulseren; Idilman, Ramazan; Bozkus, Yusuf; et al.






137

SCI

Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter

European cohort study of 737 patients with chronic hepatitis B

By: Lampertico, P.; Vigano, M.; Yurdaydin, C.; et al.

DIGESTIVE AND LIVER DISEASE Volume: 43 Supplement: 2 Pages: S103-

S104 Published: FEB 2011

138

SCI

CHARACTERIZATION OF THE INACTIVE HBSAG CARRIER STATE WITH 3

YEAR FOLLOW-UP

By: Yakut, M.; Bektas, M.; Seven, G.; et al.


Liver (EASL) Location: Berlin, GERMANY Date: 2011

Sponsor(s): European Assoc Study Liver (EASL)


S159 Meeting Abstract: 398 Published: MAR 2011

139

SCI

PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE

AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDV

RNA DECLINE AFTER LTX

By: Mederacke, I.; Filmann, N.; Yurdaydin, C.; et al.





S153 Meeting Abstract: 382













38

140

SCI

EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN

FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-

NAIVE PATIENTS WITH CHRONIC HEPATITIS B

By: Lampertico, P.; Soffredini, R.; Vigano, M.; et al.


Liver (EASL) Location: Berlin, GERMANY Date: MAR 30-APR 03, 2011




141

SCI

INTERFERON TREATMENT OF DELTA HEPATITIS: THE LONGER THE

DURATION THE BETTER THE SUCCESS?

By: Kabacam, G.; Yakut, M.; Seven, G.; et al.






142

SCI

RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE CHB:

BASELINE AND ON-TREATMENT KINETICS OF HBSAG SERUM LEVELS VARY

ACCORDING TO HBV GENOTYPE

By: Brunetto, Maurizia R.; Marcellin, Patrick; Cherubini, Beatrice; et al.

Conference: 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-

Diseases (AASLD)Location: San Francisco, CA Date: NOV 04-08, 2011


HEPATOLOGY Volume: 54 Supplement: 1 Pages: 1059A-1059A Published: OCT

2011

143

SCI

2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE

PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY

IN CLINICAL PRACTIVE

By: Lampertico, Pietro; Soffredini, Roberta; Vigano, Mauro; et al.





2011

144

SCI

DELTA HEPATITIS MAY REQUIRE PROLONGED TREATMENT WITH

INTERFERON

By: Kabacam, Gokhan; Yakut, Mustafa; Seven, Gulseren; et al.





2011














39

145

SCI

INTERLEUKIN-28 (IL-28) GENE POLYMORPHISM (RS12979860 C/T) IS

ASSOCIATED WITH PROGRESSION TO CHRONIC DELTA HEPATITIS

INFECTION

By: Bozdayi, A. Mithat; Ozturk, Tugba; Altuntas, Sara; et al.





2011

146

SCI

DISCREPANCY OF TREATMENT GUIDELINES AND LIVER BIOPSY FINDINGS

IN HEPATITIS B PATIENTS

By: Onder, F. O.; Kabacam, G.; Savas, B.; et al.


Liver (EASL) Location: Barcelona, SPAIN Date: APR 18-22, 2012



S189 Meeting Abstract: 479 Published: APR 2012

147

SCI

TENOFOVIR MONOTHERAPY FOR NAIVE PATIENTS WITH CHRONIC

HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN

302 PATIENTS FOLLOWED FOR 30 MONTHS

By: Lampertico, P.; Soffredini, R.; Vigano, M.; et al.






148

SCI

RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS

ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH

CHRONIC HEPATITIS B

By: Keskin, O.; Ormeci, A.; Kabacam, G.; et al.






149

SCI

INTERLEUKIN-28B GENE POLYMORHISM MAY AFFECT THE NATURAL

COURSE OF HEPATITIS B AND DELTA VIRUS INFECTIONS

By: Bozdayi, A. M.; Ozturk, T.; Altuntas, S.; et al.





















40

150

SCI

The impact of genetic variability of patatin-like phospholipase domain-containing 3 gene

on histological progression of non-alcoholic fatty liver disease: a cross-sectional and

longitudinal follow-up study

By: Idilman, Ramazan; Keskin, Onur; Karatayli, Senem C.; et al.

Conference: 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-

Diseases (AASLD)Location: Boston, MA Date: NOV 09-13, 2012


HEPATOLOGY Volume: 56 Supplement: 1 Pages: 884A-885A Meeting


151

SCI

Characterization of the inactive HBsAG carrier state with 4 years of follow-up

By: Yakut, Mustafa; Keskin, Onur; Seven, Guelseren; et al.





Abstract: 508 Published: OCT

152

SCI

Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with

on-treatment parameters?

By: Onder, Fatih Oguz; Erhardt, Andreas; Idilman, Ramazan; et al.






153

SCI

Implications of HBsAg, HBcAg and HDAg Immunohistochemistry in Course and

Treatment of Chronic Delta Hepatitis (CDH)

By: Kabacam, Gokhan; Wedemeyer, Heiner; Heidrich, Benjamin; et al.






154

SCI

Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-

naive patients with chronic hepatitis B followed for 3 years in a multicenter European

study

By: Lampertico, Pietro; Soffredini, Roberta; Vigano, Mauro; et al.



















41

155

SCI

Chronic hepatitis B patients with advanced fibrosis/compensated cirrhosis can benefit

from peginterferon alfa-2a (40 KD): improved or comparable response rates versus mild

fibrosis in the phase III studies

By: Piratvisuth, Teerha; Marcellin, Patrick; Gane, Edward J.; et al.






156

SCI

Pegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta:

First results of the HIDIT-2 study

By: Yurdaydin, Cihan; Wedemeyer, Heiner; Caruntu, Florin A.; et al.






157

SCI

Anti-HDV-IgM as a marker of disease activity in hepatitis delta

By: Wranke, A.; Yurdaydin, C.; Heidrich, B.; et al.

INTERNIST Volume: 54 Supplement: 1 Pages: 28-29 Published: APR 2013

158

SCI

THE EFFECT OF METFORMIN TREATMENT ON CARDIOVASCULAR RISK IN

PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

By: Keskin, O.; Idilman, R.; Evranos, B.; et al.

Conference: International Liver Congress / 48th Annual Meeting of the European-

Association-for-the-Study-of-the-Liver (EASL) Location: Amsterdam,

NETHERLANDS Date: APR 24-28, 2013




159

SCI

LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC

HEPATITIS DELTA

By: Heidrich, B.; Yurdaydin, C.; Kabacam, G.; et al.

Conference: International Liver Congress / 48th Annual Meeting of the European-

Association-for-the-Study-of-the-Liver (EASL) Location: Amsterdam,





160

SCI

A novel non-invasive fibrosis score based on cytokines and clinical parameters for the use

in chronic hepatitis delta

By: Heidrich, Benjamin; Wranke, Anika; Yurdaydin, Cihan; et al.

Conference: 64th Annual Meeting and Postgraduate Course of the American-Association-

for-the-Study-of-Liver-Diseases Location: Washington, DC Date: NOV 01-05, 2013


HEPATOLOGY Volume: 58 Special Issue: SI Supplement: 1 Pages: 725A-













42

726A Meeting Abstract: 1071 Published: OCT 2013

161

SCI

Inactive hepatitis B carriers are prone to HBsAg loss rather than reactivation: a 5-year

prospective follow-up study

By: Keskin, Onur; Yakut, Mustafa; Kalkan, Cagdas; et al.






162

SCI

Effectiveness and safety of entecavir and tenofovir in chronic hepatitis b patients: A

multicenter Turkish study in clinical practice

By: Idilman, Ramazan; Gunsar, Fulya; Keskin, Onur; et al.






163

SCI

Four years of tenofovir monotherapy for NUC naive field practice European patients

suppresses HBV replication in most patients with a favorable renal safety profile but does

not prevent HCC in patients with or without cirrhosis

By: Lampertico, Pietro; Soffredini, Roberta; Yurdaydin, Cihan; et al.






164

SCI

Anti-HDV-IgM levels as a marker of disease activity and response to pegylated

Interferon-alpha based therapy in hepatitis delta

By: Wranke, Anika; Yurdaydin, Cihan; Heidrich, Benjamin; et al.






165

SCI

Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B

(CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)

By: Papatheodoridis, George V.; Dalekos, George N.; Yurdaydin, Cihan; et al.



















43

166

SCI

96 weeks of pegylated-Interferon- alpha-2 alpha plus tenofovir or placebo for the

treatment of hepatitis delta: the HIDIT-2 study

By: Wedemeyer, Heiner; Yurdaydin, Cihan; Ernst, Stefanie; et al.






167

SCI

Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans

By: Koh, Christopher; Yurdaydin, Cihan; Cooper, Stewart; et al.





1093A Meeting Abstract: 1860 Published: 2014

168

SCI

Early on-treatment HDV RNA kinetics are not predicitve for long-term response to a

PEG-IFNa therapy of hepatitis delta

By: Wobse, Michael; Yurdaydin, Cihan; Ernst, Stefanie; et al.






169

SCI

Understanding hepatitis delta virus dynamics and antiviral efficacy of the prenylation

inhibitor lonafarnib

By: Canini, Laetitia; Koh, Christopher; Cotler, Scott; et al.






170

SCI

Timing of hepatocellular carcinoma (HCC) development and predictability of a modified

PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir

(ETV) or tenofovir (TDF)

By: Papatheodoridis, George V.; Dalekos, George N.; Sypsa, Vana; et al.






171

SCI

FOUR YEARS OF TENOFOVIR MONOTHERAPY FOR NUC NAIVE FIELD

PRACTICE EUROPEAN PATIENTS SUPPRESSES HBV REPLICATION IN MOST

PATIENTS WITH A FAVORABLE RENAL SAFETY PROFILE BUT DOES NOT

PREVENT HCC IN PATIENTS WITH OR WITHOUT CIRRHOSIS















44

By: Lampertico, P.; Soffredini, R.; Yurdaydin, C.; et al.

DIGESTIVE AND LIVER DISEASE Volume: 46 Supplement: 1 Pages: E14-

E14 Meeting Abstract: OC-28 Published: FEB 2014

172

SCI

PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH

PEGYLATED-INTERFERON-alpha-2a PLUS TENOFOVIR OR PLACEBO DOES

NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY

By: Wedemeyer, H.; Yurdaydin, C.; Ernst, S.; et al.

Group Author(s): HIDIT-2 Study Grp

Conference: 49th Annual International Liver Congress of the European-Association-for-

the-Study-of-the-LiverLocation: London, ENGLAND Date: APR 09-13, 2014


JOURNAL OF HEPATOLOGY Volume: 60 Issue: 1 Supplement: S Pages: S2-

S3 Meeting Abstract: O4 Published: APR 2014

173

SCI

PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC)

DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS

RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF)

By: Papatheodoridis, G. V.; Dalekos, G.; Sypsa, V.; et al.





S435 Meeting Abstract: P1075 Published: APR 2014

174

SCI

ENTECAVIR AND TENOFOVIR MONOTHERAPY IN TREATMENT-NAIVE

PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER TURKISH STUDY

IN CLINICAL PRACTICE

By: Idilman, R.; Keskin, O.; Gunsar, F.; et al.






175

SCI

IMPACT OF ORGAN AND NON-ORGAN-SPECIFIC AUTOANTIBODIES ON THE

TREATMENT OUTCOME OF PATIENTS WITH HEPATITIS D VIRUS INFECTION

By: Zachou, K.; Yurdaydin, C.; Drebber, U.; et al.

Group Author(s): HIDIT-1 Study Grp

Conference: 50th International Liver Congress of the European-Association-for-the-

Study-of-the-Liver Location: Vienna, AUSTRIA Date: APR 22-26, 2015




176

SCI

ON-TREATMENT HBsAg KINETICS TO PREDICT LONG-TERM HDVRNA

RESPONSE TO PEG-IFNa TREATMENT OF HEPATITIS DELTA

By: Woebse, M.; Hardtke, S.; Ernst, S.; et al.

Group Author(s): HIDIT-Study Grp















45





177

SCI

EXCELLENT 5-YEAR SURVIVAL IN CAUCASIAN CHRONIC HEPATITIS B (CHB)

PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG-TERM ENTECAVIR

(ETV) OR TENOFOVIR (TDF) THERAPY AND THE IMPACT OF

HEPATOCELLULAR CARCINOMA (HCC)

By: Papatheodoridis, G.; Dalekos, G.; Yurdaydin, C.; et al.






178

SCI

GLOBAL EPIDEMIOLOGY OF HEPATITIS DELTA: FIRST DATA FROM THE

HEPATITIS DELTA INTERNATIONAL NETWORK

By: Hardtke, S.; Abbas, Z.; Hamid, S.; et al.

Group Author(s): Hepatitis Delta Int Network






179

SCI

OPTIMIZING THE PRENYLATION INHIBITOR LONAFARNIB USING

RITONAVIR BOOSTING IN PATIENTS WITH CHRONIC DELTA HEPATITIS

By: Yurdaydin, C.; Idilman, R.; Choong, I.; et al.





S252 Meeting Abstract: O118 Published: APR 2015

180

SCI

UNDERSTANDING HEPATITIS DELTA VIRUS AND HBsAg KINETICS DURING

TREATMENT WITH PRENYLATION INHIBITOR LONAFARNIB VIA

MATHEMATICAL MODELING

By: Canini, L.; Koh, C.; Cotler, S. J.; et al.





S282 Meeting Abstract: LP36 Published: APR 2015

181

SCI

Plasma cytokine and chemokine patterns during PEG-IFNa-2a therapy of chronic hepatitis

delta

By: Woebse, M.; Schlaphoff, V.; Wranke, A.; et al.

Group Author(s): HIDIT- 2 Study-Grp
















46

Conference: 15th International Symposium on Viral Hepatitis and Liver Diseases

(ISVHLD) Location: Berlin, GERMANY Date: JUN 26-28, 2015

JOURNAL OF VIRAL HEPATITIS Volume: 22 Special

Issue: SI Supplement: 2 Pages: 108-109 Meeting Abstract: P179 Published: JUN

2015

182

SCI

The evaluation of esophageal functions by manometry in iron deficiency anemia patients

By: Bektas, M.; Kubilay, P.; Karakaya, F.; et al.

Conference: NeuroGASTRO Conference Location: Istanbul, TURKEY Date: JUN 04-06,

2015

NEUROGASTROENTEROLOGY AND MOTILITY Volume: 27 Special

Issue: SI Supplement: 2 Pages: 42-42 Published: JUN 2015

183

SCI

Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral

prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded,

placebo-controlled study in patients with chronic HDV infection

By: Koh, C.; Canini, L.; Dahari, H.; et al.

Conference: Viral Hepatitis Summit Location: Shanghai, PEOPLES R CHINA Date: APR

10-12, 2015

JOURNAL OF CLINICAL VIROLOGY Volume: 69 Pages: 247-247 Meeting

Abstract: OP0001 Published: AUG 2015

184

SCI

Prolongation of interferon therapy increases maintained virological response rates and

improves the natural course of chronic delta hepatitis

By: Keskin, Onur; Tuzun, Ali; Karakaya, Fatih; et al.






185

SCI

Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of

entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB)

patients

By: Papatheodoridis, George V.; Idilman, Ramazan; Dalekos, George N.; et al.






186

SCI

Long Term Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Patients

(CHB) with Documented Lamivudine Resistance (LAM-R): 5 Year Results From a

Randomized, Controlled Trial

By: Fung, Scott; Hann, Hie-Won; Elkhashab, Magdy; et al.


















47

187

SCI

No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) when Given Alone or

in Combination with Emtricitabine (FTC) in Chronic Hepatitis B (CHB) Patients with

Documented Resistance to Lamivudine (LAM): Final 5 Year Results

By: Berg, Thomas; Gane, Edward J.; Jablkowski, Maciej S.; et al.






188

SCI

Baseline Hepatitis B core related antigen (HBcrAg) levels predict non-response to 96-

weeks of Peg-Interferon treatment in HBV/HDV coinfected patients

By: Maasoumy, Benjamin; Woebse, Michael; Bremer, Birgit; et al.






189

SCI

HEPATITIS DELTAVIRUS KINETICS UNDER THE PRENYLATION INHIBITOR

LONAFARNIB SUGGEST HDV-MEDIATED SUPPRESSION OF HBV

REPLICATION

By: Yurdaydin, C.; Borochov, N.; Kalkan, C.; et al.

Conference: EASL International Liver Congress Location: Barcelona, SPAIN Date: APR

13-17, 2016

Sponsor(s): EASL


S587 Meeting Abstract: FRI-111 Published: 2016

190

SCI

CLINICAL UTILITY OF HEPATITIS B CORE-RELATED ANTIGEN (HBCRAG) IN

THE TREATMENT OF HEPATITIS DELTA

By: Maasoumy, B.; Woebse, M.; Hardtke, S.; et al.


13-17, 2016

Sponsor(s): EASL



191

SCI

NON-INVASIVE CLINICAL SCORES TO IDENTIFY LIVER FIBROSIS IN

HEPATITIS DELTA PATIENTS

By: Lutterkort, G. L.; Wranke, A.; Yurdaydin, C.; et al.


13-17, 2016

Sponsor(s): EASL


S361 Meeting Abstract: THU-120 Published: 2016














48

192

SCI

PHARMACOKINETICS AND PHARMACODYNAMICS MODELING OF

LONAFARNIB IN PATIENTS WITH CHRONIC HEPATITIS DELTAVIRUS

INFECTION

By: Canini, L.; Koh, C.; Cotler, S. J.; et al.


13-17, 2016

Sponsor(s): EASL



193

SCI

Comparison of Inflammatory Signal Responses of Monocytes and Hepatocytes in Mono

and Co-culture Models

By: Yazihan, Nuray; Ermis, Ezgi; Yurdaydin, Cihan; et al.

ACTA PHYSIOLOGICA Volume: 218 Special Issue: SI Supplement: 709 Pages: 66-

66 Meeting Abstract: PC107 Published: SEP 2016

194

SCI

The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral

Clearance In Patients With Chronic Delta Hepatitis

By: Yurdaydin, Cihan; Idilman, Ramazan; Kalkan, Cagdas; et al.






195

SCI

The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of

entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB)

patients

By: Papatheodoridis, George V.; Yurdaydin, Cihan; Dalekos, George N.; et al.






196

SCI

Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or

tenofovir alfenamide (TAF) Therapy In CHB Patients

By: Marcellin, Patrick; Seto, Wai-Kay; Hu, Chi-Tan; et al.






197

SCI

Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic

Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study

By: Yurdaydin, Cihan; Idilman, Ramazan; Kalkan, Cagdas; et al.



















49


198

SCI

Viral Dominance patterns are associated with distinct systemic inflammatory patterns in

patients with hepatitis delta

By: Lutterkort, Gunnar Lewon; Yurdaydin, Cihan; Wranke, Anika; et al.






199

SCI

Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than

chronic hepatitis B

By: Keskin, Onur; Karakaya, Fatih; KaIkon, Cagdas; et al.






200

SCI

The Role Of Genetic Variability Of PNPLA3 (rs738409) On Predispotion To Non-

Alcoholic Fatty Liver Disease In Lean Patients

By: Idilman, Ramazan; Karatayli, Senem C.; Karakaya, Fatih; et al.






201

SCI

Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of

Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term

entecavir (ETV) or tenofovir (TDF) therapy

By: Papatheodoridis, George V.; Dalekos, George N.; Yurdaydin, Cihan; et al.






202

SCI

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic

delta hepatitis-end of treatment results from the LOWR HDV-2 study

By: Yurdaydin, C.; Idilman, R.; Keskin, O.; et al.

Conference: International Liver Congress / 52nd Annual Meeting of the European-

Association-for-the-Study-of-the-Liver Location: Amsterdam,




S34 Meeting Abstract: GS-008 Published: 2017

203 The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients

with chronic delta hepatitis resulting in alt normalization and regression of fibrosis














50

SCI

By: Yurdaydin, C.; Idilman, R.; Kalkan, C.; et al.







204

SCI

Diversity of clinical presentation and virological characteristics of hepatitis delta in

different regions world-wide: results of the Hepatitis Delta International network

By: Wranke, A.; Hardtke, S.; Borzacov, L. M. P.; et al.







205

SCI

Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic

inflammatory patterns which influence response to interferon therapy

By: Lutterkort, G. L.; Anika, W.; Hengst, J.; et al.







206

SCI

A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the

treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 study

By: Koh, C.; Surana, P.; Han, T.; et al.






S102 Meeting Abstract: LBP-519 Published: 2017

207

SCI

Value of non-invasive fibrosis markers in chronic hepatitis D

By: Kalkan, C.; Karakaya, F.; Keskin, O.; et al.







208

SCI

LIVING DONOR LIVER TRANSPLANTATION USING ALPPS PROCEDURE: CASE

REPORT










51

By: Balci, Deniz; Kirimker, Elvan Onur; Keskin, Onur; et al.

TRANSPLANT INTERNATIONAL Volume: 30 Special

Issue: SI Supplement: 2 Pages: 544-545 Meeting Abstract: PLB035 Published: SEP

2017

209

SCI Modeling hepatitis delta virus dynamics during ritonavir boosted lonafarnib treatment-the

LOWR HDV-3 study

By: Dubey, Preeti; Koh, Christopher; Surana, Pallavi; et al.


Diseases (AASLD) / Liver Meeting Location: Washington, DC Date: OCT 20-24, 2017




KİTAPLAR VE KİTAP BÖLÜMLERİ

NO

1

Yurdaydın C, Jones EA: Hepatic encephalopathy (Book Chapter). In: Principle and Practice of

Gastroenterology and Hepatology, 2ndedition, G. Gitnict, eds., ElsevierScience Publishing Co.,

Inc. 1994; pp. 985-995

2 Wedemeyer H, Yurdaydin C. Delta hepatitis. In: Handbuch hepatitis B- Diagnostik, Verlauf,

Therapie.Uni-Med Verlag AG, HL Tillmann, ed., 2. Auflage, 2010, pp. 96-102

3

Yurdaydin C, Bozdayi AM, Idilman R, Bozkaya H. New drugs for hepatitis B: what is in the

pipeline? In: Clinical Dilemnas in Viral Liver Disease. Wiley-Blackwell Publ., GR Foster & KR

Reddy eds., 2010, pp. 226-9

4 Yurdaydin C, Idilman R. Hepatic encephalopathy. (yayın aşamasında)

5

Yurdaydın C, Walsh TJ, Engler HD, Basile AS, Jones EA.The role of gut bacteria in the

accumulation of benzodiazepine receptor ligands in hepatic encephalopathy.In: Advances in

Hepatic Encephalopathy and Metabolic Nitrogen Exchange, Capocaccia L, Merli M, Riggio O

(Eds). CRC Press, Boca Raton, FL,1995 pp. 193-7.

6

Jones EA, Yurdaydın C, Basile AS. Benzodiazepine antagonists and the management of hepatic

encephalopathy. In: Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange,

Capocaccia L, Merli M, Riggio O (Eds). CRC Press, Boca Raton, FL, 1995; pp. 549-63.

7

Basile AS, Gu Z-Q, Yurdaydın C, Harrison PM, Hughes RD, Pannell L, McKinney A, Jones EA,

Williams R. The relationship between benzodiazepine receptor ligand concentrations and the

severity of hepatic encephalopathy in humans and animal models of acute liver failure.

in:Advances in hepatic encephalopathy and metabolic nitrogen exchange, Capocaccia L, Merli M,

RiggioO(Eds).CRC Press, Boca Raton, FL,1995; pp. 198-202

8

Püspök A, Hörtnagl H, Herneth A, Steindl P, Yurdaydın C, Roth E, Ferenci P. Influence of

branched chain amino acids on glutamine levels in rats with Hyperammonemia due to urease

treatment or acute liver failure. In:Advances in Hepatic encephalopathy and metabolic nitrogen

exchange, Capocaccia L, MerliM, Riggio O (Eds).CRC Press, Boca Raton, FL, 1995; pp. 198-204.

9

Herneth AM, Püspök A, Steindl P, Yurdaydın C, Ferenci P. The influence of serotonin antagonists

on hepatic encephalopathy in rast with thioacetamide induced liver failure.In: Advances in hepatic

encephalopatyh and metabolic nitrogen exchange, Capocaccia L, Merli M, Riggio O (Eds).CRC

Press, BocaRaton, FL, 1995; pp. 254-58.



52

10

Yurdaydın C, Swain MG, Vergalla J, Paul SM, Jones EA. Effect of inhibition of ornithine

decarboxylase activity in two animal models of fulminant hepatic failure induced by hepatotoxins.

In: Advances in Hepatic Encephalopathy and Metobolism in Liver Disease, Ipswich Book Co.Ltd.,

Record CE, AL Mardini H, Eds., 1997; pp. 45-54

11

Yurdaydın C, Li Y, Ha J-H, Jones EA, Basile AS. Changes in brain and plasma opioid peptide

levels in fulminant hepatic failure: implications for antagonist therapy. In: Advances in Hepatic

Encephalopathy and Metabolism in Liver Disease, Ipswich Book Co. Ltd., Record CE, AL Mardini

H, eds., 1997; pp.21522.

12

Çınar K, Bozdayı M, Bozkaya H, Uzunalimoğlu Ö, Erekul S and Yurdaydın C. Hepatic

encephalopathy (Book Chapter). Possible mechanisms of the hepatoprotective effect of

difluoromethylornithine on Thioacetamide –induced fulminant hepatic failure in the rat.. Inc. 1999;

pp. 59-66

13 Cınar K, Uzunalimoğlu O, Erekul S, Bozkaya H, Bozdayı M, Yurdaydin C. NAcetylcysteine in

Thiocetamide induced toxic hepatitis in rats. 1999;pp. 453-459.

14

Çelik T, Gören MZ, Gürdal H, Çinar K, Törüner M, Değim T, Uzbay IT, Bozkaya H and

Yurdaydin C. Hepatic encephalopathy. (Book Chapter). Is fatigue of 2 cholestasis mediated by

altered central serotoninergic neurotransmission? Inc. 2003; pp. 165-171.

15 Göktürk S, Deda G, Bozkaya H and Yurdaydin C. Hepatic encephalopathy.(Book Chapter).

Naloxone treatment of human hepatic encephalopathy. Inc. 2003;pp. 369-374.

16 İnfeksiyon Hastalıkları ve Mikrobiyolojisi. Editörler: Willke A, Söyletir G, Doğanay M. Nobel Tıp

Kitabevleri, İstanbul, 2002. 2.baskı, sayfa 847-52: ISBN: 975-420-202-4

17 Karaciğer Hastalıkları El kitabı. Editör: Prof.Dr. Muzaffer Gürakar. İstanbul Tıp Kitabevi, İstanbul

2012. 4.Baskı, sayfa 103-118, ISBN 978-605-4499-31-1

18 A’dan Z’ye Hepatitler. Editörler:Prof.Dr. Muzaffer Gürakar, Prof.Dr. Ulrich Leuschner, Doç. Dr.

Ahmet Gürakar, Doç.Dr. Zeki Karasu, İstanbul, 2007. 3.Baskı:ISBN 975-6395-75-3

19 Yurdaydin C. Immunohistochemistry for viral hepatitis: Methods andapplications. In:Biomarkers

in Liver Disease: Vinood B Patel andVictor R Preedy eds; Springer-Nature; 2017; pp.719-733

ÇALIŞILAN ÜLKE DIŞINDA DAVET ÜZERİNE YAPILAN KONUŞMALAR

NO KONUŞMA BAŞLIĞI; YAPILDIĞI YER; TARİH; DAVET EDEN KURUM/KURULUŞ

1 EASGEN (European Association of Gastroenterology and Nutrition) Postgraduate Course, Varna,

Bulgaristan, 21-23/06/2012: “Progress in antiviral therapies for chronic hepatitis B, C and D”

2 9th Infectious Diseases Symposium, Catania, Italya, 12/05/2012: “Delta hepatitis: An update”

3 47thEASL (European Association for the Study of the Liver)Meeting Early Morning Session

konuşması, Barselona, İspanya, 18-22/04/2012: “Delta hepatitis”

4 APASL (The Asian Pacific Association for the Study of the Liver ) Meeting, Taipei, Tayvan, 16-19/02/2012: “Natural history and treatment of delta hepatitis”

5 5th Paris Hepatitis Conference, 30-31/01/2012: “How to optimize treatment of G1 chronic hepatitis C patients”

6 19th UEGW (United European Gastroenterology Week), Postgraduate Kurs konuşması,

Stockholm, İsveç, 22-26/10/2011: “Challenges of long-term treatment of chronic hepatitis B”

7 Current Situation in Liver Disease in Mongolia International Conference, Ulanbataar, Mogolistan,

23/09/2011: “Hepatitis B, C and D: Current treatment options in a developing country

8 3rd Congress of the African Middle East Digestive Cancer Alliance, 4-5/02/2011, Rabat, Fas: “Prevention of hepatocellular carcinoma in patients with chronic viral hepatitis: the WGO perspective”

https://www.google.com.tr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CCoQFjAA&url=http%3A%2F%2Fapasl.info%2F&ei=uEzYUJDhJKqI4gSijIHwAw&usg=AFQjCNE81bk1ckHopXW2rnULPyK1FTm5ng&bvm=bv.1355534169,d.Yms

53

9 Egypt Postgraduate Course and Endo Workshop, 12/2010, Kahire, Misir: ”a. Delta hepatitis: an update; b. Pathogenesis and treatment of hepatic encephalopathy

10 18th UEGW (United European Gastroenterology Week), Postgraduate Kurs konuşması, Barselona,

İspanya, 23-27/10/2010: “Treatment decisions in chronic hepatitis B”

11 4th AMAGE (African Middle East Association of Gastroenterology) Congress, 15-17/10/2010: “Do we still use lamivudine in hepatitis B?”

12 EASL (European Association for the Study of the Liver) Single Topic Conference on Delta hepatitis, Istanbul, 24-26/09/2010: “Natural history and treatment of delta hepatitis”

13 Prag Hepatology Meeting, 16-18/09/2010: “Interferon treatment of chronic hepatitis B”

14 MASL (Meditteranean Association for the Study of Liver) Meeting, Napoli, Italya, 14-16/06/2010: “How to prevent resistance to antivirals”

15

13th International Symposium on Viral Hepatitis, 14-17/07/2010, Salvador, Bahia, Brezilya: “a. Prevention of resistance to antivirals; b. Interferon as a finite treatment alternative for chronic hepatitis B; c. European Guidelines for the management and treatment of hepatitis B and D; Hepatitis delta in non-endemic areas- an emerging disease?”

16

7th National Clinical Academic Conference on Liver Diseases of the Chinese Association for the Study of the Liver: EASL Day, 11/06/2010, Xiamen, Çin: “Treatment of chronic hepatitis B: Interferons or NUCs: a perspective of European Hepatologists”

17 45th EASL (European Association for the Study of the Liver)Meeting Early Morning Session konuşması, Viyana, Avusturya, 14-18/04/2010: “Viral Hepatitis and Immunosuppression”

18 8th Congress of the Jordanian Society of Gastroenterology, 25-27/03/2010: “a. EASL Guidelines on hepatitis B; b. Pathogenesis of hepatic encephalopathy”

19 1stOman Hepatology Meeting, 02/2010, Muskat, Oman Sultanlığı: Chronic hepatitis B in clinical practice

20 6th APASL (Asian Pacific Association for the Study of the Liver) Single Topic Conference on Acute Liver Failure, 01/2010: “Hepatitis B: Role of de-novo infection, reactivation and delta virus”

21 17th Viral Hepatitis B and C Meeting of Athens, 30-31/01/2010: “Lamivudine still remains in wide use in chronic hepatitis B: why, when and where?”

10. WOS veritabanına göre H-indeksi: 37

Documents

ÖZGEÇMİŞ Prof. Dr. Cihan YURDAYDIN · seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a hepatitis D patient during